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ABSTRACT  
Lysosomal Storage Disorders (LSDs) are different inherited diseases caused by the 
deficit of lysosomal or non-lysosomal proteins, resulting in the accumulation of 
undegraded substrates in lysosomes. Recent studies support the idea that LSDs are 
associated with a global impairment of the entire endo-lysosomal compartment, 
specifically of autophagy involved in the principal lysosome-related degradative 
pathway. However little is known about the mechanisms underlying such 
dysfunction. Identification of these mechanisms is crucial for the development of 
precisely targeted therapies for LSDs. 
In this work I demonstrate that secondary accumulation of cholesterol on lysosomal 
membranes is the principal molecular mechanism at the basis of lysosomal and 
autophagosomal dysfunction, as it affects the fusogenic ability of lysosomal 
membranes. Specifically cholesterol overload affects the distribution and function of 
SNARE proteins, a protein superfamily involved in fusing vesicular membranes with 
targeted lysosomal membranes. 
In addition I propose a novel gene therapy approach for the treatment of Pompe 
Disease, an LSD characterized by glycogen accumulation. This approach relies on the 
AAV-mediated over-expression of the TFEB gene, a master regulator for lysosomal-
autophagosomal biogenesis that is able to partially rescue the lysosomal glycogen 
storage by increasing the functionality of the lysosomal-autophagosomal pathway. 
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INTRODUCTION 
 
1 LYSOSOME 
 
1.1 General characteristics 
 
The lysosome was discovered in 1959 by Christian De Duve [2] and has since been 
the subject of intense studies that have clarified the majority of its cellular functions. 
Lysosomes are organelles delimited by a single membrane and filled with digestive 
enzymes that are able to degrade molecules and structures into their elementary 
constituents. Therefore they represent the final destination for many endocytic and 
autophagic secretion molecules targeted for degradation or recycling. Furthermore 
lysosomes are involved in various specific cellular pathways such as autophagic 
degradation of molecules, matrix modelling, pathogen defence and plasma membrane 
repair via lysosomal exocytosis. 
Lysosomes originate from the fusion between endosomes and the Golgi’s hydrolytic 
vesicles. The Golgi’s hydrolytic vesicles, also called primary lysosomes, already 
contain all necessary hydrolases, but its local pH is not sufficiently acidic for their 
activation. Therefore lysosomal enzymes are activated only after the primary 
lysosome fuses with endosomes, as the latter carries proton pumps necessary for the 
acidification of the lumen. 
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The lysosomal membrane is very important for lysosomal structure and function as it 
protects cells from hydrolytic lysosomal enzymes. Moreover it is particularly 
enriched with glycosylated proteins which are important for the transportation of 
substrates and functional proteins involved in synthetic processes and trafficking.  
Although it is often just considered an “enzyme-filled bag”, the lysosome has 
numerous cellular roles, and its physiological importance is confirmed by the various 
storage disorders caused by defects in lysosomal biogenesis, or by reduced or absent 
degradation ability [3] 
 
1.2 Lysosomal membrane structure 
 
Lysosomal membrane constituents were discovered about 20 years ago: they include 
cholesterol, sphingolipids, a unique phospholipid composition [4], an abundance of 
carbohydrates [5] and different membrane proteins, which are responsible for 
maintaining the integrity of the entire organelle. Membrane proteins are highly 
specialized for different functions; for example proton pumps keep the lumen 
acceptably acidic, and carrier proteins translocate the products of hydrolytic 
degradation, such as amino acids, simple sugars and small lipids. 
Lysosomal membrane proteins are also involved in fusion with other organelles like 
autophagosomes, plasma membrane and others lysosomes [6]. The SNARE (Soluble 
NSF Attachment Protein REceptors) protein family is particularly important for the 
fusogenic capability of lysosomal membranes as it represents the minimal machinery 
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required for membrane fusion. SNARE proteins are classified as vesicle SNAREs (v-
SNAREs), located on the vesicles membrane, and target SNAREs (t-SNAREs), 
located on the membranes of target compartments. SNAREs may vary in size and 
composition, but they all share a 60-70 amino acid cytosolic domain (SNARE motif) 
that can assemble into trans-SNARE complexes. The trans-complex, formed by four 
helical bundles, contains three SNARE proteins: a v-SNARE on one membrane, and 
two t-SNAREs (in this case one of the t-SNAREs carries two SNAREs motifs) on the 
opposing membrane. The trans-SNARE complex interacts with soluble carriers that 
trigger its ability to mediate membrane fusion by inducing local physical stress on the 
bilayer. When the membranes fuse, the trans-SNARE complex becomes cis-SNARE 
complex, because after fusion, the SNARE proteins are no longer designated to 
opposing membranes, but instead share the single resulting fused membrane. The 
components can then de-assemble by way of other soluble factors; at this point each 
SNARE that was involved in the fusion process is now free from complex and is 
recycled back to its original compartment to mediate new rounds of fusion. 
Experiments with monoclonal and polyclonal antibodies [7, 8] reveal a high content 
of glycosylated integral proteins, which are enriched both with lysosomes and late 
endosomes. Such proteins are designated as Lysosome Associated Membranes 
Proteins (LAMPs), Lysosomal Membranes Glicoproteins (LGPs) and Lysosomal 
Integral Proteins Membranes (LIMPs). 
Given its peculiar composition, the lysosomal membrane covers both structural and 
functional roles. For one it separates acidic hydrolase from the other cellular 
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constituents to prevent unwilling degradation. It also mediates different cellular 
processes such as translocation of substrates targeted for degradation, and even fusion 
with organelles like autophagosomes, for degradation, or with plasma membrane and 
others lysosomes [6], for membrane repair. 
 
1.3 Lysosomal content 
 
The lysosomal lumen is densely filled with various hydrolases (phosphatases, 
nucleases, proteases, polysaccharidases, oligosaccharidases and lipases) responsible 
for all of the degradative processes of lysosomes. These enzymes are not only limited 
to the degradation of specific substrates, but are also involved in many lysosome-
mediated cellular processes such as bone remodeling, propagation and formation of 
metastases, antigen presentation, hormone processing and plasma membrane repair. 
To date more than 50 lysosomal hydrolases have been identified, but the precise 
mechanisms behind their roles in cell metabolism are far from being completely 
understood [9]. Lysosomal hydrolases are active at a pH between 4.5 and 5.0, so the 
lysosomal lumen is constantly maintained at this acidic pH value as a result of the   
activity of the proton pumping V-type ATPase. This membrane protein uses 
metabolic energy in the form of ATP to pump protons in the lysosomal lumen.  
Because the activity of the V-ATPase generates a transmembrane voltage, another 
ion, called a counter-ion, needs to move across the membrane to dissipate this 
membrane potential. A specific ion transporter moves the counter-ion in or out of the 
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lysosome; the transporter may render the counter-ion an anion upon influx or a cation 
after efflux. Several ion transporters have been identified, but there remain other 
unknown transporters. 
 
1.4 Transport Systems 
 
The lysosome plays a central role in cellular trafficking pathways, being the final 
destination for macromolecular products of endocytic and biosynthetic pathways. For 
example the low density lipoprotein (LDL) is quickly interiorized by endosomes and 
routed to lysosomes after binding with specific receptors on the cellular surface, 
while acidic hydrolases are synthetized in the ER, modified with Mannose-6-
phosphate at the cis-Golgi and, finally, transported to lysosomes through the trans-
Golgi network (TGN) by way of a specific Mannose-6-phosphate receptor (M6PR). 
Lysosomes are the central hub linking the different sorting systems. At the plasma 
membrane, molecules can remain either on the cellular surface or be interiorized into 
endosomes and routed to lysosomes. Molecules may also travel between plasma 
membranes and endosomes via the TGN. In addition endosomes allow for them to be 
recycled back to plasma membrane or sent to lysosomes. All molecular trafficking is 
regulated by a specific molecular machinery capable of recognizing and directing the 
molecules to their final destinations [10]. 
Lysosomes are not only involved in degradation and recycling processes, but also in 
regulating cellular interaction with the extracellular environment. In fact lysosomes 
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are involved in a secretory pathway, called lysosomal exocytosis, which plays a 
major role in different physiological processes such as cellular immune response, 
bone reabsorption and plasma membrane repair [11-13]. Lysosomal exocytosis 
requires two sequential steps: in the first step, that is Ca2+ independent [14], 
lysosomes are recruited to the close proximity of the cell surface, while in the second 
step the pool of pre-docked lysosomes fuse with the plasma membrane in response to 
Ca2+ elevation [11, 12]. Ca2+-dependent lysosomal exocytosis was considered to be 
limited to specialized secretory cells; however, recent studies indicate that this 
process occurs in all cell types [11, 15, 16]. 
Although the main steps of lysosomal exocytosis have been elucidated, little is 
known about its regulation or its coordination with lysosomal biogenesis. 
 
1.5 Lysosomal biogenesis 
 
The importance of lysosomes in cellular functions and its association with different 
diseases has led to extensive research on lysosomal biogenesis. Currently there are 
two models being proposed for lysosomal biogenesis: the maturation model and the 
vesicular transport model [17, 18]. 
The maturation model suggests that endosomes, formed by plasma membrane 
internalization, are transformed into lysosomes by the addition and removal of 
molecules. According to this model endosomes mature into lysosomes and without 
endocytosis lysosomes would not be formed. 
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The vesicular transport model suggests that endosomes, late endosomes and 
lysosomes are pre-existing structures that communicate by continuous rounds of 
fusion and fission. It is commonly believed that neither hypothesis can adequately 
describe lysosome formation, and consequently, a final model will retain elements 
from both hypotheses. 
Recent publications have allowed the identification of a gene network regulating 
lysosomal biogenesis and function in response to different environmental cues. The 
first relevant discovery was of a new transcription factor, named TFEB 
(Transcription Factor EB) [19] that positively regulates the expression of genes 
involved in lysosomal and autophagosomal biogenesis and function regulation [20]. 
Specifically in normal conditions TFEB is prevalently cytoplasmic, stress (when 
more lysosomes and autophagosomes are needed) causes it to translocate to the 
nucleus where it activates the transcription of lysosomal and autophagosomal related 
genes. TFEB functions by binding the promoters of regulated genes in a consensus 
sequence called the CLEAR sequence (and defining the so called “CLEAR network”) 
[21]. 
Interestingly TFEB translocation in the nucleus is mediated by different 
environmental cues; one in particular links autophagy to lysosomal biogenesis in 
response to nutrient deprivation [22]. TFEB interacts with the nutrient sensor 
complex mTORC1 on lysosomal membrane, and when nutrient are present, 
phosphorylation of TFEB by mTORC1 inhibits TFEB activity, while inhibition of 
mTORC1 by starvation or lysosomal dysfunction causes TFEB dephosphorylation 
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and nuclear translocation [22]. 
 
2 LYSOSOMAL STORAGE DISORDERS 
 
Lysosomal Storage Disorders (LSDs) are a group of about 50 diseases characterized 
by an accumulation of undegraded molecules inside the lysosome, resulting in the 
formation of large intracellular vacuoles. They are usually caused by lack of a 
lysosomal hydrolases, or by lack of its activator or transporter, causing the 
accumulation of a specific substrate in lysosomes for each disorder type.  
LSDs are inherited by autosomal recessive traits, except for Fabry Disease, Hunter 
Disease (MPSII) and Danon Disease, which are caused by X-linked recessive traits. 
The clinical phenotypes are vast, as they can vary for age of onset, severity of 
symptoms and central nervous system manifestation. In fact many LSDs have three 
different onset forms: infantile, juvenile and adult.  
The severity and progression of a Lysosomal Storage Disorder may vary depending 
on the type of primary accumulation, the types of cells or tissues that cause 
accumulation of the substrate, the genetic background or the environmental influence.  
It is strongly believed that cells and tissues have certain thresholds of enzymatic 
activities below which clinical manifestation occurs. This may explain how an 
infantile form and a juvenile/adult form of the same disease can affect different 
tissues. For example, the ß-galactosidase deficiency, which in the infantile form 
causes severe brain disease, has no brain involvement in the juvenile form.  
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LSDs can be classified relating to the altered pathway and substrate accumulation: 
• Defects in glycan degradation, the most common group of LSDs, represented 
by about 30 disorders. It can be divided into four subgroups: defects in 
degradation of glycoprotein, glycolipid, glycosaminoglycan or glycogen 
• Defects in lipid degradation 
• Defects in protein degradation 
• Defects in lysosomal transporters 
• Defects in trafficking 
 
2.1 Multiple Sulfatases Deficiency (MSD) 
 
MSD is a very rare LSD in which all the sulfatases are deficient [23, 24]. Sulfatases 
are hydrolases that cleave sulfate esters from a wide range of substrates such as 
glycosaminoglycans (GAGs), sulfolipids, and steroid sulfates [25]. This protein 
family is represented in most eukaryotes and prokaryotes, with some notable 
exceptions such as Saccharomices cerevisiae. While in prokaryotes sulfatases are 
involved in sulphur scavenging, in vertebrates they are implicated in the turnover and 
degradation of sulfated compounds, mostly complex molecules that are hydrolysed in 
lysosomes in concert with acidic glycosidases. Functional correlation among 
sulfatases is reflected in a high degree of amino acid sequence similarity along the 
entire length of the proteins, suggesting that they have evolved from a common 
ancestral gene [25, 26].  
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MSD is an autosomal recessive disorder caused by the lack of activity in the 
Formylglycine Generating Enzyme (FGE), coded for by the SUMF1 gene. The FGE 
enzyme resides in the Endoplasmic Reticulum (ER) and catalyses the conversion of a 
specific glycine into formyl-glycine in the active site of all the cellular sulfatases. 
This is a post-translational modification essential for the activity of the sulfatases. 
The inactivation of FGE, due to loss-of-function in the SUMF1 gene, results in an 
impairment of sulfatases’ ability to degrade their specific substrates, leading to the 
accumulation of different types of macromolecules (especially GAGs) in lysosomes. 
MSD is a multi-systemic disease that recapitulates the phenotypes of all the other 
LSDs due to a deficit in a single sulfatase, and this is especially true for symptoms 
regarding the central nervous system (CNS). In fact a progressive and massive 
neuronal and glial death in the CNS of MSD patients and mice models has been 
reported. This is thought to be due to accumulation of undegraded materials and the 
subsequent inflammatory response, suggesting that apoptosis is the final pathogenic 
step in LSDs. 
The FGE enzyme, although an ER resident, lacks ER-sorting signals in its sequence, 
but recently we have demonstrated that its retention in the ER is mediated by the PDI 
protein, which acts as a chaperone for the FGE enzymatic activity [27]. In addition 
the FGE enzyme can take part in paracrine signalling when reabsorbed by 
neighbouring cells [28]. We have also demonstrated that FGE trafficking (retention 
vs. secretion) is precisely regulated by its interaction with two protein shuttles, 
ERP44 and ERGIC53, which regulate its movement between the ER and the Golgi 
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apparatus. 
Since MSD recapitulates all the phenotypic manifestations of the LSDs it has been 
widely used as a model to identify the pathogenic mechanisms leading to cell death in 
LSDs. In our laboratory we developed a transgenic mouse model for the MSD in 
which the SUMF1 coding region is broken by the insertion of the ß-geo cassette 
[29].The MSD mouse model obtained has no sulfatase activity, and the phenotype is 
as severe and progressive as that observed in human patients. 
From a clinical point of view, affected individuals show neurologic deterioration with 
mental retardation, skeletal anomalies, organomegaly, and ichthyosis. Different types 
of MSD can be distinguished according to the age of onset: neonatal, late infantile (0 
to 2 years), and juvenile (2 to 4 years). Neonatal MSD is the most severe form with a 
broad range of mucopolysaccharidosis-like symptoms and death within the first year 
of life. Late-infantile MSD, which includes the majority of cases, resembles late-
infantile metachromatic leukodystrophy with progressive loss of mental and motor 
abilities and skeletal changes. There is also an attenuated form of late-infantile MSD 
with onset beyond the second year of life. Rare cases of juvenile-onset MSD have 
been reported with onset of symptoms in late childhood and slower progression [30]. 
 
2.2 Mucopolysaccharidosis type IIIA (MPS-IIIA) 
 
Mucopolysaccharidosis type IIIA (MPS-IIIA or Sanfilippo syndrome) belongs to a 
subgroup of LSDs, called the mucopolysaccharidoses (MPSs), caused by the 
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deficiency of lysosomal enzymes responsible for the catabolism of GAGs [31]. MPS-
IIIA arises from the congenital loss-of-function of sulfamidase (SGSH), a sulfatase 
enzyme involved in the stepwise degradation of heparan sulfate (HS). There are three 
other subtypes of MPS-III (MPS-IIIB, C and D), all of which are caused by 
deficiencies in different enzymes required for HS catabolism. MPS-IIIA is the most 
frequent subtype in some populations and the most common of the MPS disorders 
[32]. 
In MPS-IIIA the CNS is the predominant site of pathology. In fact, although the 
somatic organs are affected in MPS-IIIA, the dominant clinical features are 
neurological dysfunction and neurocognitive decline. As a result, patients experience 
a wide range of symptoms, including delayed development, mental retardation, rapid 
loss of social skills and learning ability, disturbed sleep, aggression and hyperactivity 
[31]. The phenotype of MPS-IIIA is very complex, and not only due to the 
intracellular accumulation of undegraded GAGs, but also to their secretion in the 
extracellular matrix.  
There exists a mouse model for the MPS-IIIA resulting from a natural missense 
mutation in the SGSH gene with a consequent 3% reduction in the enzymatic activity 
with respect to WT littermate [33]. MPS-IIIA mice present the accumulation of 
heparan sulfate from birth, hyperactivity at the third week of age and aggression from 
the tenth week of age [34, 35]. The disease progression in mice is very similar to that 
observed in human patients, so this model is widely used to study the pathogenic 
mechanisms at the basis of the disease and the effects of different possible therapies. 
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2.3 Pompe Disease (PD) 
 
Pompe disease is a severe metabolic myopathy caused by the deficiency of acid 
alpha-glucosidase (GAA) an enzyme responsible for breaking down glycogen to 
glucose within the acidic environment of lysosomes. The functional deficiency or 
complete absence of the enzyme results in accumulation of glycogen within this 
cellular compartment [36, 37]. PD pathology is also characterized by secondary 
accumulation of autophagic debris (autophagic build-up), typically found in skeletal 
muscle fibres [38-40]. 
Even if GAA deficiency is a systemic disorder (distended glycogen-filled lysosomes 
can be found in multiple tissues) the principal pathological effect of the storage is on 
skeletal and cardiac muscles.  
Pompe Disease has different severity and age-onset in patients: in the most serious 
infantile form, the disease manifests as profound weakness, hypertrophic 
cardiomyopathy, heart failure, feeding difficulties, respiratory infections and, if left 
untreated, causes death within the first year of life. In the attenuated phenotypes, 
characterized by later (childhood, juvenile or adult) onset, cardiac muscle is usually 
spared, but the illness remains a serious condition with progressive motor 
impairment, respiratory failure and premature death [37]. 
A transgenic mouse model for PD has been generated by knocking-out the GAA gene 
[41]. GAA -/- mice show different phenotypes at different ages, recapitulating both 
the infantile and adult form of PD, so they are a useful tool for the study of PD 
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pathology and therapy. At 3 weeks of age, GAA -/- mice begin to accumulate 
glycogen in lysosomes due to the lack of GAA activity, and the accumulation 
increases progressively thereafter. By 3.5 weeks of age, these mice have markedly 
reduced mobility and strength. However they grow normally, reach adulthood and 
remain fertile throughout their lives. By 8-9 months of age animals develop obvious 
muscle wasting and a weak, waddling gait [41]. 
 
3 THERAPIES FOR LSDs 
 
Few therapies are available for LSDs, and treatments are mostly symptomatic as they 
are not able to completely revert the pathologic phenotype. There are different trials 
and procedures in experimental testing mainly based on enzyme replacement therapy, 
bone marrow transplantation, ex-vivo and in-vivo gene therapy, enzyme enhancement 
therapy and substrate reduction. 
However the lack of complete knowledge of the pathogenic mechanisms behind the 
disease is still problematic when developing new therapeutic approaches to the 
treatment of LSDs.  
 
3.1 Enzyme Replacement Therapy (ERT) 
 
ERT consist of the administration of a recombinant WT form of the lacking enzyme 
directly into the haematic circulation of LSDs patients. ERT is based on the discovery 
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that the metabolic defect of cultured fibroblasts from mucopolysaccharidosis patients 
can be compensated by addition of corrective factors which proved to be the wild 
type counterparts of the deficient lysosomal enzymes [42]. The added enzymes are 
rapidly internalized into the lysosomal compartment where they catabolize the 
accumulated substrates. Importantly only 1-5% of the normal cellular activity was 
required for correction. The detection of this corrective mechanism led to the 
optimistic prediction that LSDs should be generally treatable by administration of the 
respective intact lysosomal enzyme, a treatment strategy designated as enzyme 
replacement therapy (ERT). 
The uptake of lysosomal enzymes into the lysosomal compartment of fibroblasts and 
other cells depends on receptor-mediated endocytosis via a Mannose 6-phosphate 
receptor (M6PR). The M6PR binds Mannose-6-phosphate residues (M6P) which are 
normally added to a sulfatase amino acid chain in the Golgi. M6PR residues play a 
central role in sorting sulfatases from the Golgi to lysosomes biosynthetically and in 
their uptake from the extracellular matrix. After binding at the cell’s surface, the 
receptor-ligand complexes cycle from the plasma membrane to an endosomal 
compartment where the ligands dissociate and reach the lysosome, and 
contemporarily, the receptors are recycled back to plasma membrane. Due to this 
peculiar trafficking pathway, ERT is a good candidate for the treatment of all the 
LSDs caused by a mutation in lysosomal enzymes. 
ERT of animal models for various LSDs such as MPS-I [31], MPS-IIIB [43], MPS-
VI [44, 45], MPS-VII [46], Fabry disease [47], Niemann-Pick disease [48] and 
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Pompe disease [49] revealed that intravenously infused lysosomal enzymes are 
rapidly internalized by liver, spleen and other peripheral tissues, but usually do not 
enter the brain parenchyma in therapeutically efficient amounts. As a consequence 
the visceral, but not the CNS, pathology can be improved. 
The CNS is not reached by the recombinant enzyme, principally due to the activity of 
the Blood Brain Barrier (BBB), so several efforts were undertaken to favour the 
delivery to CNS. Studies in a mouse model of MPS-VII revealed that recombinant β-
glucuronidase is able to reach the brain parenchyma when it is injected into newborns 
whose BBB is still leaky [50]. Two weeks later, however, the BBB is fully 
differentiated and prevents further uptake of enzyme from the circulation. 
Other attempts to overcome the BBB comprise invasive strategy such as 
intracerebroventricular infusion or temporary disruption of the tight junctions 
between cerebral endothelial cells, by infusing hypertonic solutions, [51], and non-
invasive strategy based on conjugates between blood-brain shuttle vectors and 
therapeutic enzymes [52, 53]. A recent work demonstrated the efficacy of gene 
delivery of a modified SGSH for the correction of CNS lesions in MPS-IIIA mice 
[54]. In this work the authors show that the addition of the blood brain barrier binding 
domain (BD) from the Apolipoprotein B (ApoB-BD) to the SGSH enzyme is able to 
mediate the BBB crossing and allow the SGSH to efficiently reach the CNS, resulting 
in the correction of CNS lesions. 
 
3.2 Bone Marrow Transplantation (BMT) 
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This approach arises from the idea that a fraction of newly synthesized lysosomal 
enzymes is not targeted to lysosomes, but instead released from a “producer” cell to 
be re-absorbed by neighbouring cells [55, 56]. Several experiments demonstrated that 
the transfer of a therapeutic enzyme from a WT producer cell to an enzyme-deficient 
cell is able to achieve metabolic correction of the deficient cell in a process called 
cross-correction. 
The discovery of cross-correction allowed the development of a new therapeutic 
strategy: the supply of a deficient cell is achieved by transplantation of enzyme-
producing cells, which transfer the enzyme by a release/uptake mechanism or direct 
cell-to-cell transfer to neighbouring cells. 
In BMT producer cells are bone marrow-derived microglial cells that are able to 
repopulate the CNS [57-59]. It has been reported that BMT therapy in a cat model of 
α-mannosidosis, is able to lead to the appearance of α-mannosidase in neurons and 
other cells of the CNS concomitant with the loss of intracellular storage vacuoles 
[56]. Treated cats showed little or no progression of neurologic signs 1-2 years post-
transplant, whereas untreated cats became severely impaired and reached end-stage 
disease by 6 months of age. 
However, further BMT trials in animal models were less effective in most cases, and 
no improvement of the brain pathology was detectable, e.g., in a cat model of GM2 
gangliosidosis treated by an identical protocol [60]. 
The variability of therapeutic success may be due to differences of enzyme 
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production, modification and secretion from producing cells. 
Clinical studies for BMT protocol in human patients have been done since 1980, 
especially for mucopolysaccharidoses, and showed that BMT is able to ameliorate 
visceral symptoms, such as hepatosplenomegaly, respiratory problems and cardiac 
function, and might even arrest or slow down neurological deterioration [61, 62]. 
However as for ERT, the efficacy of BMT is dependent on different factors, such as 
the age of therapy and the kind of enzyme missing, and even if BMT can have a 
beneficial effect on visceral symptoms, and to a lesser extent on bone disease, the 
effect on neurological symptoms varies. Furthermore BMT generally does not result 
in a normal phenotype and is associated with a mortality rate of 10%, even if an 
HLA-identical donor is available [63, 64], so the risks and possible benefits of BMT 
need to be balanced carefully for each individual patient. 
 
3.3 Ex-vivo Gene Therapy 
 
The classical BMT approach can be enhanced by taking advantage of the recent 
knowledge of cDNA expression and vector packaging systems. In fact donor cells 
can be genetically modified by ex vivo gene therapy prior to transplantation. The 
rationale for this approach is explained by the elevation of the enzyme production and 
delivery by constitutive expression of the correcting enzyme from a strong, usually 
viral promoter. Furthermore ex vivo gene therapy allows the use of the patient’s own 
cells as enzyme-producers, thereby eliminating the risk of immune responses to 
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unmatched donor cells or graft-versus-host disease [65]. 
The most promising approach in this field is that of hematopoietic stem cell mediated 
gene therapy. The effects of conventional BMT and bone marrow stem cell gene 
therapy have been compared in a mouse model of MPS-I [66]. 
Transplantation of unmodified WT bone marrow was effective in reducing storage in 
liver and spleen, but not in kidney or brain. Gene therapy using bone marrow 
overexpressing human α-L-iduronidase from a retroviral vector, however, also 
corrected the pathology of kidney, choroid plexus, and thalamus. This study clearly 
supports the notion that bone marrow stem cell gene therapy can be superior to 
conventional BMT. 
In larger animals, including man, retrovirus-based gene therapy is associated with 
particular problems. Autologous bone marrow from dog models of fucosidosis and 
MPS-I, which was transduced with retroviral vectors encoding α-fucosidase and α-L-
iduronidase, respectively, failed to engraft after transplantation [67, 68]. Indeed 
authors supply evidence that the non-myeloablated recipients developed a cellular 
immune response that specifically eliminated transgene-expressing donor-type cells. 
Unstable engraftment as well as low transduction efficiency was also noticed in a 
clinical trial analysing the fate of retrovirally transduced autologous CD34+ cells 
after transplantation into Gaucher patients [69]. Due to these complications, the bases 
of which are not fully understood, bone marrow stem cell gene therapy has not been 
successfully applied to larger animals so far. 
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3.4 In vivo Gene Therapy 
 
The discovery of vector systems, also infecting non-dividing cells, allowed the 
development of a new kind of therapy, based on the delivery of the WT form of the 
mutated gene directly in vivo [65]. Viral vectors for gene therapy are not able to 
replicate in cells because they have a defective genome that only carries the genes for 
infection.  
Gene therapy is in theory a good option for all the cases in which the correcting 
enzyme is not able to reach missing cells due to the lack of internalization signals as 
observed in some cases of ERT or BMT. 
There are different studies using adenovirus, adeno-associated virus or retrovirus 
vectors as vehicles for gene-transfer into living organisms. 
Adenoviruses carry their genetic material in the form of dsDNA and are able to infect 
both dividing and non-dividing cells. After infection they are not able to integrate 
their genetic material’s content into the genome of the hosting cell. Therefore the 
transgene expression is only transient and no longer achieved after cell division. For 
this reason treatment with the adenovirus will require constant re-administration. 
Adenoviruses are largely used as vectors because their lack of integration into the 
host cell’s genome may prevent the outbreak of unwanted collateral effects, such as 
cancer. There are different works showing improvements of pathology in visceral 
organs but not in CNS of mouse models of LSDs after systemic injection of 
adenoviruses carrying the WT form of the mutated gene [70-73]. Another study 
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showed that it is possible to achieve a partial restoration of CNS pathology by 
injecting adenoviral vectors directly into the brain [74]. 
Adeno-associated viruses (AAVs) are only able to replicate in a cell already infected 
by an adenovirus since they require adenoviral machinery for replication. AAVs 
carry their genetic material in the form of dsDNA and are able to infect both dividing 
and non-dividing cells. Different from adenoviral vectors, AAV vectors can integrate 
into the host genome, resulting in a more stable transgene expression even if they are 
principally non-integrating viruses. Low immunogenicity and lack of inflammatory 
side effects are further advantages of this vector class. Systemic injections of AAV 
into newborn mice have been reported to be effective for the treatment of both 
systemic and CNS pathology, even if the major effect on CNS is achieved only by 
intra-cerebral injections [75]. 
Retroviral vectors integrate into the host genome but are only able to infect dividing 
cells. Even if they are not very attractive for gene therapy due to the limitation of 
infective abilities, retroviruses have been used in therapy because of their large 
packaging capacity and their integrating property, which can result in a long-term and 
stable expression of the enzyme. [76, 77]. 
 
3.5 Enzyme Enhancement Therapy 
 
This approach exploits the residual activity of the mutant endogenous enzyme in mild 
phenotypes, for example, those due to misfolding or mutation out of the active site. 
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In particular two different strategies have been proposed for therapy: the first one 
utilizes protease inhibitors which may increase the half-life of misfolded, but 
lysosomally targeted, enzymes by reducing their proteolytic degradation rate [78]. 
The second one utilizes co-chaperones that are specific small-molecule ligands that 
bind to the catalytic site of an enzyme and rescue mutant polypeptides by assisting 
their correct folding in a pre-lysosomal compartment [79]. 
 
3.6 Substrate Reduction Therapy 
 
This approach aims to reduce the amount of storage acting on the anabolic pathway 
rather than the catabolism of substrates, for example with the use of inhibitors for the 
de novo synthesis of substrates [80, 81]. Interestingly a combination between BMT 
and SRT further prolonged survival, indicating a synergistic effect between the two 
treatment strategies [82]. Due to good results of knockout mice combination therapy, 
it might therefore be especially advantageous for early-onset forms of the disease 
characterized by a very low or absent residual enzyme activity. 
 
4 PATHOGENESIS IN LSDs 
 
Even if primary and secondary storages (not directly related to the missing enzyme) 
have been largely described and studied, little is known about the effects of storage 
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on cell vitality and their link to pathogenesis in LSDs. Different theories have been 
proposed [83]: alterations in lysosomal functionality, intracellular trafficking and 
signalling or interference with gene expression.  
On one hand the accumulation of undegraded material results in the alteration of 
lysosomal membrane function and structure determining the leakage of lysosomal 
enzymes into the cytosol. Thus can lead to the activation of lysosome-mediated 
apoptotic pathway [84, 85]. On the other hand, lysosomal storage can interfere with 
the trafficking and sorting functions of lysosomes, thus resulting in the alteration of 
sub-cellular localization of receptors and enzymes. Furthermore the accumulation of 
undegraded materials can interfere with the functionality of other cellular pathways 
determining the secondary accumulation of toxic compounds, as in the case of 
psicosin [86]. 
Moreover cellular storage can interfere with gene expression regulation determining 
the activation of particular apoptotic genes. For example it has been reported that in 
the CNS of LSDs with a neurological phenotype, there is an over-activation of pro-
inflammatory genes in the microglial compartment with a consequent inflammation-
related neuronal death [87-89]. 
Recently it has been reported that the autophagic pathway plays a pivotal role in 
mediating cell death and pathology in LSDs. Autophagy is a degradative pathway in 
which double-membraned organelles (autophagosomes), containing cytoplasmic 
molecules and organelles, have to fuse with lysosomes for the degradation of their 
cargoes. Autophagy mediates the degradation of big molecules and maintains the 
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turnover of cytoplasmic organelles. It is very important for cellular vitality, vertebrate 
development and immune response. 
The autophagic rate is finely regulated in response to different stimuli such as 
nutrient deprivation, cytoplasm remodelling during embryogenesis, oxidative damage 
response and prevention of aggregation of toxic molecules in cytoplasm [90-92]. It 
has been reported that blocking autophagy leads to neurodegeneration in KO mice for 
autophagic genes [93, 94].  
In our laboratory and in other studies, it has been reported that the deactivation of 
autophagy is due to an alteration in lysosomal fusogenic capability, and leads to the 
accumulation of toxic aggregates and damaged organelles in the cytoplasms of cells 
derived from various mouse models of LSDs [95-100]. 
However little is known about the mechanisms of lysosomal storage that lead to an 
impediment of the autophagy, even if this is an important point for the treatment of 
LSDs because the restoration of this particular pathway can be a good target for 
therapy. 
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AIM OF THE THESIS 
 
The molecular mechanisms at the basis of cellular and tissue pathology in LSDs are 
not yet fully characterized. Moreover current therapies, mainly based on the 
restoration of the enzymatic activity that is lost, are insufficient in completely 
restoring normal conditions.  
The principal aim of this work is then to first identify a pathologic molecular 
mechanism common to all LSDs and to use the deriving knowledge to develop a new 
therapeutic approach to LSDs. 
In particular in the first part of my work, I studied lysosomal membrane properties 
and functions in mouse embryonic fibroblast (MEFs) derived from mouse models of 
MSD and MPS-IIIA. Specifically I demonstrated that the accumulation of cholesterol 
in these two LSD models causes an altered organization of the endolysosomal 
membranes, resulting in the expansion of regions enriched in this lipid. Cholesterol 
accumulation on lysosomal membrane affects the fusogenic capability of lysosomes 
by sequestering SNARE proteins in unproductive complexes and impairing their 
recycling.  
In the second part of my work I developed a new therapeutic approach for the 
treatment of LSDs that circumvents the problem of inefficient enzymatic activity, 
typical of all classic therapeutic approaches, by exploiting the ability of lysosomes to 
expel their content into the extracellular space, thus providing clearance of the stored 
material [101]. Specifically I characterized the effect of TFEB overexpression in a 
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mouse model of Pompe Disease. Expression of TFEB in myotubes and muscle fibres 
resulted in lysosomal fusion with plasma membrane, lysosomal exocytosis and a 
consistent reduction of intra-lysosomal glycogen accumulation. In addition TFEB 
overexpression in muscle of PD mice alleviated autophagic pathology by promoting 
the formation and removal of autophagolysosomes. 
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RESULTS 
 
1 IDENTIFICATION OF THE MOLECULAR PATHOGENIC MECHANISM 
IN LSDs 
 
1.1 Lysosomal fusion is impaired in LSDs 
 
The trafficking of lysosomes, endosome and autophagosomes is impaired in both 
MSD and MPS-IIIA. Figure 1 shows that epidermal growth factor (EGF) stimulation 
lysosomal-mediated degradation of EGF receptor (EGFR) is more efficient in wild-
type (WT) cells than in LSD cells.  
 
 
 
 
 
 
Fig. 1 EGFR degradation is impaired in LSD cells. EGFR degradation was followed in MSD, 
MPS-IIIA and WT MEFs by treating the cells with EGF for the indicated time to stimulate 
EGFR internalization. The cells were immediately lysed and subjected to anti-EGFR blotting. 
The amount of remaining EGFR was quantified by densitometry analysis (ImageJ) of the blot 
and expressed in the chart as % of the EGFR amount present at time T0 (100%). The values in 
the chart represent the mean ± s.e.m. values of three independent experiments. *P<0.05, 
Student’s t-test: WT versus MSD and WT versus MPS-IIIA. 
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We also performed a transport assay by loading cells with a fluorescently labelled 
dextran, showing that after 6h of chase, the percentage of dextran delivered to 
lysosomes (as revealed by the co-localization between dextran and the lysosomal 
marker LAMP1) is significantly higher in WT compared to that in LSD cells (Fig. 2).  
 
 
 
 
Thus indicates that in LSD cells the traffic of membranes to the lysosomal 
compartment is impaired. We analysed the rate of fusion between lysosomes and 
autophagosomes using a tandem fluorescent-tagged autophagosomal marker in which 
LC3 was engineered with both monomeric red fluorescent protein (mRFP) and GFP. 
In this assay the GFP fluorescence loss is a direct measurement of autophagosome 
fusion because of GFP quenching by lysosomal acidic pH [1]. The validity of this 
analysis is not affected by the decreased degradation capability of lysosomes in the 
Fig. 2 Dextran uptake is impaired in LSD cells. MSD, MPS-IIIA and WT MEFs cells loaded 
with dextran (alexafluor-594-conjugated) were labelled with anti-LAMP1 antibody and the 
percentage of dextran co-localizing with LAMP1 was evaluated. The chart displays merge 
values (mean ± s.e.m.) that represent the percentage of dextran co-localizing with LAMP1 
measured in 15 different cells of triplicated experiments. *P<0.05, Student’s t-test: WT versus 
MSD and WT versus MPS-IIIA at each time point. Scale bar: 10 µm. 
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LSD models analysed, as the green fluorescence is rapidly quenched by protonation 
occurring in the acidic lysosomal lumen (Fig. 3A). Specifically WT and LSD cells 
were transfected with the mRFP-GFP-LC3 construct, and the autophagosome 
maturation was followed over a 3h period. The rate of autophagosome maturation 
was markedly slower in LSD cells compared to that of WT cells (Fig. 3B). 
All of these findings indicate a decreased delivery of cargo to the lysosomes and an 
impaired ability of lysosomes to fuse with target membranes in LSD cells. 
 
 
 
 
 
1.2 Cholesterol accumulates in the endolysosomal membrane of LSDs reducing 
Fig. 3 Lysosomal fusion is impaired in LSD cells. The rate of lysosome fusion with 
autophagosomes was monitored in MSD, MPS-IIIA and WT MEFs transfected with a tandem 
fluorescently tagged LC3 [1]. The rate of autophagosome maturation reflected the percentage of 
LC3 “unfused” (green/red ratio) at each time (1 and 3 h) after bafilomycin removal (T0). The 
percentage of the LC3 “unfused” was displayed versus the value at T0 (assumed to be 100%). 
Values are represented as means ± s.e.m of triplicate experiments *P<0.05, Student’s t-test: WT 
versus MSD and WT versus MPS-IIIA at each time point. Scale bar: 10µm. 
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the efficiency of lysosomal fusion 
 
To analyse lysosomal membrane structure and properties, we isolated lysosomes and 
late endosomes from LSD and WT MEFs using a magnetic chromatography 
procedure [102]. We observed increased levels of cholesterol in membranes from 
LSD lysosomes compared to those in WT (Fig. 4A). This is consistent with Filipin 
staining, showing that cholesterol accumulated inside the endolysosomal vesicles and 
decorated LAMP1-positive membrane regions (Fig. 4B)  
. 
 
 
 
 
Importantly no significant changes in the bulk of phospholipids were observed, with 
the exception of an increase in lysobisphosphatidic acid (LBPA) (Fig. 5A and B). 
Fig. 4 Cholesterol accumulation in endolysosomal membrane from LSD cells. (A) 
Cholesterol levels were measured in the indicated endolysosomal membrane samples containing 
an equal amount of proteins and expressed as ng of cholesterol per µg of protein. Values 
represent the means ± s.e.m values of three independent experiments *P<0.05, Student’s t-test: 
WT versus MSD and WT versus MPS-IIIA. (B) Filipin staining showing cholesterol 
accumulation in the endolysosomal compartment of MSD and MPS-IIIA MEFs (Arrowheads 
and enlarged images). Scale bar, 10 µm (B) 
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We tested the effect of cholesterol accumulation on lysosomal fusogenic capability 
by modulating cholesterol level in the endolysosomal membranes from WT and LSD 
cells and then monitoring lysosomal fusion efficiency. Specifically we achieved 
cholesterol overloading on lysosomal membranes of WT cells by treatment with 
methyl-β-cyclodextrin (MβCD)-complexed cholesterol (Fig. 6A), while we achieved 
cholesterol depletion from lysosomal membranes of LSD cells by the treatment with 
MβCD (Fig. 6B).  
Fig. 5 Alteration in lipid composition of endolysosomal membranes from LSD cells. (A, B) 
Total lipids extracted from the indicated endolysosomal membrane sample (30 µg of proteins) 
were either (A) subjected to a phosphate assay to quantify the bulk of phospholipids or (B) 
separated by TLC. Phospholipids and cholesterol on TLC plates were revealed by molybdenum 
blue staining. CHOL, cholesterol; LBPA lysobisphosphatidic acid; PC, phosphatidylcoline; PE 
phosphatidylethanolamine; PI phosphatidylinositol; SM, sphingomyelin. 
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Cholesterol overloading in WT cells resulted in a decreased rate of both 
autophagosome maturation (Fig. 7A) and lysosomal endocytic transport (Fig. 8A), 
and conversely, cholesterol depletion in LSD cells resulted in a normalization of both 
autophagosome maturation (Fig. 7B) and lysosomal endocytic transport (Fig. 8B). 
These findings indicate that abnormal cholesterol levels in the endolysosomal 
membrane directly affect the ability of lysosomes to efficiently fuse with target 
membranes in the cells.  
Fig. 6 Cholesterol modulation in LSD and WT cells. Endolysosomal membrane cholesterol 
measurements and Filipin staining were carried out in either (A) WT MEFs loaded with 
cholesterol or in (B) MSD and MPS-IIIA MEFs treated with MβCD. Arrowheads and enlarged 
images show cholesterol accumulation in endolysosomes of cholesterol-loaded WT MEFs. 
Values are represented as means ± s.e.m of triplicate experiments *P<0.05, Student’s t-test: (A) 
WT versus WT+cholesterol; (B) MSD versus MSD+MβCD and MPS-IIIA versus MPS-
IIIA+MβCD. Scale bar, 10 µm (A,B). 
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1.3 The organization of the endolysosomal membranes is altered in LSD cells 
 
Fig. 7 Cholesterol accumulation inhibits lysosomal/autophagosomal fusion. WT MEFs 
were overloaded with cholesterol (A) while MSD and MPS-IIIA were treated with MβCD 
(B). After treatments the rate of autophagosome maturation were also analysed as in Figure 1. 
Values are represented as means ± s.e.m of triplicate experiments *P<0.05, Student’s t-test: 
(A) WT versus WT+cholesterol; (B) MSD versus MSD+MβCD and MPS-IIIA versus MPS-
IIIA+MβCD. 
 
Fig. 8 Cholesterol accumulation inhibits lysosomal/endosomal fusion. WT MEFs were 
overloaded with cholesterol (A) while MSD and MPS-IIIA were treated with MβCD (B). After 
treatments the transport of dextran to lysosomes was also analysed as in Figure 2. Values are 
represented as means ± s.e.m of triplicate experiments. *P<0.05, Student’s t-test: (A) WT 
versus WT+cholesterol; (B) MSD versus MSD+MβCD and MPS-IIIA versus MPS-
IIIA+MβCD. Scale bar, 10 µm (A, B). 
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Biological membranes have a peculiar structural organization in which cholesterol 
plays various roles. For example it increases lateral heterogeneity and determines the 
segregation of a subset of lipids and proteins into ordered domains which are 
enriched with cholesterol and glycosphingolipids. It has been proposed that these 
membrane domains constitute discrete entities termed “lipid rafts”, which mediate 
important function in membrane signalling and trafficking [103-106]. The 
components of these cholesterol-enriched regions are resistant to detergents, thus 
allowing for biochemical coalescence into an insoluble fraction, termed detergent-
resistant membranes (DRMs), which can be isolated after centrifugation in a sucrose 
gradient [107] and identified by Flotillin-1 immunostaining. 
The analysis of DRMs in endolysosomal membranes of LSD and WT cells showed 
an increase in the percentage of Flotillin-1 associated with DRMs of LSD cells (Fig. 
9), indicating an increased amount of cholesterol-enriched regions in these 
endolysosomal membrane samples.   
 
 
 
  
 
Fig. 9 LSD endolysosomal membrane contains increased amount of detergent resistant 
domains (DRMs). Endolysosomal membranes from MSD, MPS-IIIA and WT MEFs were 
treated with 1% Triton X-114 and loaded on a sucrose gradient. Immunoblots with Flotillin-1 
identified DRMs in fractions 2, 3 and 4 (arrows). The fractions at the bottom of the gradient (12 
and 13) correspond to high-density detergent soluble fractions, whereas the remaining ones were 
defined as intermediate fractions (intermediate-I: 5, 6, 7 8; intermediate-II: 9, 10 and 11). The 
percentage of Flotillin-1 in DRMs was calculated from the densitometric quantification of 
immunoblots. Values are represented as means ± s.e.m of triplicate experiments. *P<0.05, 
Student’s t-test: WT versus MSD and WT versus MPS-IIIA. 
36 
 
 
This was also supported by immuno-electron microscopy (EM) analysis, which 
showed an accumulation of the glycosphingolipid GM-1, a component of cholesterol-
enriched membrane domains in the membranes of LSD endolysosomes (Fig. 10). 
 
 
 
 
We also measured membrane order of the isolated membranes using the fluorescent 
probe C-laurdan [108]. Notably, despite the overall increase in DRMs and GM1 
levels, LSD endolysosomal membranes maintain a membrane order that is similar to 
that observed in WT cells (Fig. 11). This may be due to a general and proportional 
build-up of both raft and non-raft membrane regions, and is consistent with previous 
reports of an expansion of the endolysosomal compartment in LSD cells [109]. 
 
 
 
Fig. 10 The LSD endolysosomal membrane contains increased amount of cholesterol-
enriched regions. Immuno-EM of GM1 lipid was carried out in WT, MSD and MPS-IIIA MEFs 
by staining cells with anti-cholera toxin B antibodies (see Materials and methods section). The 
number of GM1-positive dots was measured in 25 cells from three independent experiments and 
displayed as fold to WT. Values are represented as means ± s.e.m of triplicate experiments. 
*P<0.05, Student’s t-test: WT versus MSD and WT versus MPS-IIIA. Scale bar, 0.3 µm. 
 
Fig. 11 The LSD endolysosomal membranes maintain a membrane order similar to WT 
endolysosomal membranes. Endolysosomal membranes from MSD, MPS-IIIA and WT MEFs 
were stained with C-laurdan and subsequently analyzed by fluorescence spectrophotometry to 
calculate the GP value (see Materials and methods section for details). Distribution of 
cholesterol was also measured throughout the gradient and expressed as percentage of total 
cholesterol in raft (DRMs) and soluble fractions. Values are represented as means ± s.e.m of 
triplicate experiments. *P<0.05, Student’s t-test: WT versus MSD and WT versus MPS-IIIA 
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Cholesterol changes on LSD endolysosomal membranes is associated with an 
increase in the amount of DRM-associated proteins and a decrease in the amount of 
proteins present in the soluble regions of the gradient with respect to the protein 
distribution observed in control samples (Fig. 12). This aberrant protein 
compartmentalization is restored by MβCD treatment, which leads to a reduction of 
DRM fraction (Fig. 12). 
 
 
 
 
The increase of DRM proteins is specific for a peculiar sub-set of proteins, as 
demonstrated by a similar distribution profile of the transferrin receptor in WT and 
LSD cells, that is normally excluded from DRMs, and the distribution of LAMP1, 
which has a more linear distribution across the gradient (Fig. 13). Our results suggest 
a cholesterol-mediated reorganization of a subset of endolysosomal membrane 
proteins. 
Fig. 12 LSD endolysosomal membranes show an abnormal protein content in LSD cells. 
Equal aliquots from either DRMs or soluble fractions were pooled, the protein content 
determined and displayed as percentage of total protein in DRM and soluble gradient regions. 
Values are represented as means ± s.e.m of triplicate experiments. *P<0.05, Student’s t-test: WT 
versus MSD and WT versus MPS-IIIA for each fraction. 
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1.4 Endolysosomal SNARE membrane compartmentalization is highly 
dependent on cholesterol and is altered in LSD cells 
 
SNAREs are transmembrane proteins that drive membrane fusion in endocytic 
pathways by assembling into high-affinity trans-complexes between two opposing 
membranes [110, 111]. Previous studies have demonstrated that plasma membrane 
SNAREs are functionally organized into clusters, the integrity of which is dependent 
on cholesterol [112-116]. To elucidate the effect of membrane cholesterol 
abnormalities observed in LSD endolysosomes on SNAREs functionality, we 
analysed the lysosomal membrane distribution of VAMP7, Vti1b and syntaxin 7, 
which are post-Golgi SNAREs belonging to differential combinatorial set of 
SNAREs.  These post- Golgi SNAREs participate in trans-complexes and drive the 
fusion of endolysosomal membranes with either endosomes or autophagosomes 
[117]. Our results shows that these SNAREs become detergent-resistant in LSD cells, 
as we observed that VAMP7, Vti1b and syntaxin 7 are more associated with DRM 
Fig. 13 Protein distribution on endolysosomal membranes is altered in LSD cells. 
Immunoblotting profiles of the transferrin receptor and LAMP1 in the sucrose gradient.  
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regions at the expense of the SNARE content present in the soluble region of the 
gradient (Fig. 14A and B). This SNARE redistribution across the endolysosomal 
membrane is cholesterol-dependent as demonstrated by cholesterol depleting or 
loading, respectively, in LSD and WT cells. Treatment of LSD cells with MβCD 
resulted in the dissociation of SNAREs from the DRMs, restoring a SNARE 
distribution similar to that observed in WT cells (Fig. 14A and B). Conversely, 
loading WT cells with cholesterol resulted in an increased association of SNAREs 
with DRM regions, thus mimicking the conditions observed in LSD cells (Fig. 14A 
and B). 
 
 
 
 
 
 
 
 
These findings were associated with a remarkable enrichment of VAMP7, Vti1b and 
Fig. 14 SNAREs are sequestered by cholesterol within endolysosomal membranes. (A) 
VAMP7, Vti1b and syntaxin 7 distributions in endolysosomal membranes from MSD, MPSIIIA 
and WT MEFs were evaluated by immunoblotting analysis of gradient fractions. To simplify 
the analysis the DRM, the intermediate-I, the intermediate-II and soluble fractions of the 
gradient were pooled separately and then subjected to immunoblotting. SNARE distribution was 
also analyzed after loading WT cells with cholesterol and after MβCD treatment. In MSD and 
MPSIIIA MEFs, all analyzed SNAREs abnormally accumulate in DRMs of lysosomal 
membranes. Cholesterol modulation results in a change of SNARE distribution. (B) The 
percentage of each analyzed SNARE observed in DRM fractions was quantified from blots 
(ImageJ densitometry analysis) and displayed as relative amount versus WT. Values are 
represented as means ± s.e.m of triplicate experiments. *P<0.05, Student’s t-test: WT versus 
MSD, WT versus MPS-IIIA, WT versus WT+cholesterol, MSD versus MSD+MβCD, MPS-
IIIA versus MPS_IIIA+MβCD for each analysed SNARE. 
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syntaxin 7 in the endolysosomal membranes of both cholesterol-loaded and LSD 
cells, which was significantly higher compared with that observed for LAMP1 (Fig. 
15 and Fig. 16), the distribution of which was not affected by DRM and was similar 
in WT and LSD cells (Fig. 13).  
 
 
 
 
 
 
 
 
 
 
 
 
However we observed a limited increase in the amount of the analysed SNAREs in 
total cell lysates (Fig. 17) whereas LAMP1 showed a more significant increase (Fig. 
Fig. 15 SNARE proteins are overexpressed on endolysosomal membranes of cholesterol-
loaded cells. Immunoblots and relative quantification showing SNARE protein levels along 
with LAMP1 protein levels in endolysosomal membranes from WT (untreated and cholesterol 
treated) and MSD MEFs (untreated and MβCD treated). In the graphs, the protein levels were 
displayed as relative amount versus WT. Values are represented as means ± s.e.m of triplicate 
experiments. *P<0.05, Student’s t-test: WT versus MSD, WT versus WT+cholesterol and MSD 
versus MSD+MβCD for each analysed protein. 
 
Fig. 16 VAMP7 distribution is affected in LSD cells. WT and MSD MEFs transfected with 
GFP–VAMP7 were stained with anti-GFP for immuno-EM. The enlarged image shows 
internalization of GFP–VAMP7 particles (arrow). Scale bar, 0.3 µm. 
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17), consistent with the expansion of the endolysosomal compartment in LSD cells. 
 
 
 
 
This suggests that SNARE accumulation in endolysosomal membranes is the result of 
an increased cholesterol-mediated sequestration in specific membrane regions, rather 
than that of slower degradation kinetics due to the reduced degradation capacity of 
lysosomes in LSDs. Importantly we observed no evidence of altered membrane 
compartmentalization of the non-lysosomal SNAP23 and Sec22/syntaxin 5 SNAREs 
that showed a similar distribution in WT and LSD cells (Fig. 18A). Moreover, 
distribution abnormalities of cholesterol-dependent lysosomal membranes affected 
SNARE proteins specifically and did not affect other crucial membrane components 
of the traffic apparatus, as shown by the normal distribution observed for Rab7 (Fig. 
18B), a well-established regulator of endocytic membrane trafficking [118]. 
Fig. 17 SNARE proteins are overexpressed in cholesterol-loaded cells. Immunoblots and 
relative quantification showing SNARE protein levels along with LAMP1 protein levels in total 
lysates from WT (untreated and cholesterol treated) and MSD MEFs (untreated and MβCD 
treated). In the graphs, the protein levels were displayed as relative amount versus WT. Values 
are represented as means ± s.e.m of triplicate experiments. *P<0.05, Student’s t-test: WT versus 
MSD, WT versus WT+cholesterol and MSD versus MSD+MβCD for each analysed protein. 
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1.5 Endolysosomal SNAREs are locked in assembled complexes in LSD cells 
 
The function of SNARE requires an ordered dynamic interaction between different 
SNAREs with consecutive rounds of assembly, membrane fusion and disassembly of 
post-fusion SNARE cis-complexes [111]. Moreover to maintain membrane identity 
and ensure new fusion events, post-fusion SNAREs must be trafficked and recycled 
back to steady-state membrane locations by interacting with specific adaptors of the 
clathrin vesicular transport [119-122]. We investigated the effect of abnormal 
SNARE accumulation in DRM of LSD endolysosomal membranes on these dynamic 
interactions, and thus on SNARE functions. 
We first analysed the ability of SNAREs to undergo a correct assembly-disassembly 
reaction. The amount of assembled SNARE complexes was determined by measuring 
SNARE complexes levels in boiled and non-boiled SDS treated samples. We found 
an increase in the amount of SDS-resistant complexes in LSD cells compared with 
Fig. 18 Association with DRM is specific for SNARE proteins in LSD cells. Syntaxin 5, 
Sec22 and SNAP23 distribution in total membrane derived from control WT and MSD MEFs. 
Syntaxin 5 immunoblot shows two bands (*, 35 kDa and **, 42 kDa) corresponding to the two 
isoforms of the protein. (G) Distribution profile of Rab7 in WT and MSD lysosomal 
membranes. Values are represented as means ± s.e.m of triplicate experiments.  
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that in WT and an increased association of these complexes in DRM fractions, as 
revealed by immunoblot against Vti1b (Fig. 19).  
 
  
 
 
 
 
 
 
 
Fig. 19 SNAREs are locked in high molecular weight complexes in LSD endolysosomal 
membranes. SDS-resistant complexes containing Vti1b were detected by immunoblotting 
analysis of non-boiled samples corresponding to total, detergent insoluble (DRM) and detergent 
soluble (Sol.) endo-lysosomal membrane fractions derived from MSD and WT MEFs. The SDS-
resistant complexes were also visualized after loading WT MEFs with cholesterol and after 
treating MSD MEFs with MβCD. Immunoblots revealed the presence of low molecular weight 
complexes (*, 50–60 kDa) and high molecular weight complexes (**,480 kDa). The percentage 
of Vti1b in SDS-resistant complexes in total endolysosomal membranes (bottom-left chart) and 
the amount of Vti1b-containing SDS-resistant complexes in DRM and soluble fractions (bottom-
right chart) were calculated by the densitometric quantification of the correspondent 
immunoblots (ImageJ). Values represent the mean ± s.e.m. values of three independent 
measurements. *P<0.05, Student’s t-test: WT versus MSD, WT versus WT+cholesterol and 
MSD versus MSD+MβCD (bottom-left chart); WT versus MSD, WT versus WT+cholesterol 
and MSD versus MSD+MβCD for each fraction (bottom-right chart). 
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These data were confirmed by the increase in the amount of co-immunoprecipitation 
of syntaxin 7 and VAMP7 with Vti1b in LSD cells with respect to WT cells (Fig. 20).   
 
 
 
The abnormal distribution of endolysosomal SNARE complexes in LSD cells was 
rescued by cholesterol depletion, whereas cholesterol loading in WT cells resulted in 
the formation of abnormal complexes (Fig.19 and Fig. 20). The blotting profile of 
SDS-resistant complexes indicated the accumulation of both lower and higher 
molecular weight complexes that were also decorated by the Vti1b cognate SNARE 
syntaxin 7 (Fig. 21). These complexes may represent, respectively, SNARE dimers 
and oligomer/fully assembled cis-complexes, or alternatively may reflect nonspecific 
pairing of SNAREs due to their local enrichment in cholesterol membrane 
microdomains. There was also the evidence of the accumulation of SNARE 
homodimers containing either Vti1b or syntaxin 7, as shown by the shift of the main 
band present in the lower molecular weight complexes in the syntaxin blot (Fig. 21). 
Fig. 20 Snare proteins are locked in assembled form in LSD endolysosomal membranes 
Syntaxin 7 and VAMP7 were co-immunoprecipitated with Vti1b using anti-Vti1b antibodies in 
WT (untreated or cholesterol treated) and in MSD (not treated or MβCD treated) MEFs. The 
amount of Vti1b precipitated in each cell line is also shown. 
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The α-SNAP adaptor is essential for the recruitment of N-ethylmaleimide-sensitive 
factor (NSF) on assembled cis-complexes for the post-fusion complex disassembly 
[123, 124]. In addition the NSF-SNAP system has been demonstrated to operate also 
on some off-pathway SNARE complexes and on SNARE-assembling intermediate 
complexes [125-127]. We observed that the accumulation of SNARE complexes in 
both cholesterol-loaded and LSD cells was associated with a mislocalization of α-
SNAP that resulted more associated with intracellular membrane than with cytosol 
(Fig. 22). Moreover this mislocalization was rescued by cholesterol depletion from 
LSD endolysosomal membranes (Fig. 22). This suggested that the SNARE 
complexes accumulating in cholesterol-loaded and LSD cells could represent “dead-
end”/intermediate or post-fusion complexes undergoing inefficient or partial 
disassembly. 
 
 
Fig. 21 SNARE complexes in LSD cells are associated to DRMs. SDS-resistant complexes 
are decorated by anti-syntaxin 7 antibodies in total endolysosomal membrane fraction from WT 
and MSD MEFs 
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These findings demonstrate an abnormal cholesterol-dependent accumulation of 
SNARE complexes in the endolysosomal membranes of LSD cells and indicate an 
imbalance in the SNARE assembly-disassembly functional cycle. 
 
1.6 The traffic and recycling of post-Golgi endolysosomal SNAREs is inhibited 
in LSD cells 
 
The sorting and recycling of post-fusion SNAREs is mediated by specific interaction 
with dedicated clathrin adaptors. Co-immunofluorescence analysis showed an 
increased co-localization between VAMP7 and Vti1b in LSD cells compared to WT 
(Fig. 23). Moreover this co-localization took place mostly in LAMP1-positive 
structures (white merge in Fig. 23), suggesting that SNARE clustering is associated 
with trapping the lysosomes in LSD cells.  
Fig. 22 α-SNAP is more associated with endolysosomal membrane in LSD cells. Membrane-
associated α-SNAP and its release in the cytosol were evaluated by western blot analysis on total 
cell lysates, intracellular membranes recovered after centrifugation from a post-nuclear 
supernatant fraction (membrane associated) and cell lysates devoid of membranes (cytosolic 
released) derived from MSD (untreated or MβCD treated) and WT (untreated or cholesterol 
treated) MEFs. 
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In normal conditions Vti1b is transported from a late endosomal compartment back to 
an earlier compartment and/or the trans-Golgi network (TGN) through the clathrin 
adaptor EpsinR [119, 121]. We examined the effect of accumulation of SNARE-
complexes in endolysosomal membranes of LSD cells on Vti1b interaction with 
EpsinR and found a marked decrease of Vti1b co-localization with EpsinR in LSD 
and cholesterol-overloaded cells (Fig. 24). However the Vti1b overlap with EpsinR 
increased in LSD cells depleted of cholesterol (Fig. 24). 
Fig. 23 Increased co-localization of SNARE proteins in LSD cells. MSD, MPS-IIIA and WT 
MEFs were subjected to a triple labelling with anti-VAMP7, anti-Vti1b and anti-LAMP1 
antibodies. The merges between VAMP7 and Vti1b (double merges in yellow) and between 
VAMP7, Vti1b and LAMP1 (triple merges in white) are shown (see also enlarged images 
showing the extent of co-localization in different regions of the cells). The VAMP7–Vti1b co-
localization was quantified in 15 different cells and displayed as % of Vti1b co-localizing with 
VAMP7 (means ± s.e.m.). *P< 0.05, Student’s t-test: WT versus MSD and WT versus 
MPSIIIA. Scale bar: 10 µm. 
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We confirmed the effect of cholesterol abnormalities in endolysosomal membranes of 
LSD cells on Vti1b recycling by following the dynamics of Vti1b trafficking route to 
the TGN in live cells using fluorescence recovery after photobleaching (FRAP) 
experiments. The fluorescence of transfected GFP-tagged Vti1b (GFP-Vti1b) was 
photo-bleached in a TGN juxta-nuclear region, and its recovery was tracked for 120-
180s. The recovery of GFP-Vti1b fluorescence was faster in WT cells than observed 
in LSD cells (Fig. 25), indicating an impairment in the Vti1b transport from 
endolysosomal compartment towards the TGN in LSD cells due to the reduced 
Fig. 24 Cholesterol levels affect SNARE localization. Co-localization of Vti1b with EpsinR 
was quantified by double-labeling experiments in MSD and MPS-IIIA (untreated and MβCD 
treated) and in control WT (untreated and cholesterol treated) MEFs. The chart displays merge 
values (means ± s.e.m.) that represent the percentage of Vti1b co-localizing with EpsinR 
measured in 15 different cells. *P< 0.05, Student’s t-test: WT versus MSD, WT versus MPS-
IIIA, WT versus WT+cholesterol, MSD versus MSD+MβCD and MPS-IIIA versus 
MPSIIIA+MβCD). Scale bar: 10 µm. 
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interaction with the EpsinR transporter. Interestingly cholesterol depletion in LSD 
cells was able to increase the mobility of Vti1b (Fig. 25), whereas cholesterol 
overloading in WT cells resulted in a slowed Vti1b FRAP-kinetics, similar to that 
observed in LSD cells (Fig. 25). These results demonstrate that the sorting and 
vesicular transport of post-Golgi SNAREs are impaired in LSD cells due to 
cholesterol-dependent SNARE clustering that affects SNARE interaction with 
clathrin adaptors. 
 
 
 
 
2 LINKING THE MOLECULAR PHENOTYPE TO THE TREATMENT FOR 
LSD 
 
The identification of this important pathological mechanism in LSD allowed us to 
develop new therapeutic approaches for the treatment of LSD. We took advantage of 
our lab’s recent identification of a transcription factor (TFEB), that is the master 
Fig. 25 Cholesterol levels affect SNARE trafficking. Vti1b trafficking was monitored by 
FRAP analysis in WT (untreated and cholesterol treated) and MSD (untreated and MβCD 
treated).  MEFs transfected with GFP–Vti1b (see Materials and methods section for details). 
FRAP data are displayed as percentage of recovery with respect to the fluorescence before 
bleach (100%) and are representative of 10 recordings from different cells. A summary of t1/2 
values is also shown. *P< 0.05, Student’s t-test: WT versus MSD, WT versus WT+cholesterol, 
MSD versus MSD+MβCD. 
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regulator of lysosomal and autophagosomal compartment biogenesis [19-21]. In 
particular we demonstrated that TFEB overexpression is able to positively regulate 
the expression and function of genes involved in lysosomal and autophagosomal 
compartment biogenesis. In addition we also demonstrated that TFEB overexpression 
is able to modulate cellular clearance in LSD cells by increasing lysosomal docking 
to plasma membrane and exocytosis [101].  
So if the principal pathological mechanism is storage build-up in cells leading to 
lysosomal dysfunction, our hypothesis was to utilize TFEB overexpression to 
increase lysosomal and autophagosomal functions, and in particular, their exocytosis 
to mediate cellular clearance. We tested our hypothesis in both an in vitro and in vivo 
model of Pompe Disease (PD). 
 
2.1 TFEB overexpression reduces lysosomal size and glycogen burden in PD 
myotubes 
 
To verify if TFEB can promote lysosomal exocytosis and rescue lysosomal glycogen 
storage, PD myotubes isolated from the GAA -/- mouse were infected with an 
adenovirus vector expressing Flag-TFEB (Ad-TFEB), and were then fixed and 
immunostained with the lysosomal marker anti-Lamp1 and anti-Flag antibodies. 
After 42-78 h post-infection cells showed a robust overexpression, and nuclear 
staining of TFEB resulting in a dramatic reduction of lysosomal size (Fig. 26A and 
B). PD myotubes infected with the adenovirus vector (Ad-null) showed large 
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LAMP1-positive lysosomes similar to those in non-infected PD cells (Fig. 26A).  
 
 
 
 
 
 
At 24h post-infection cells showed a relocation of enlarged lysosomes toward the 
plasma membrane (fig. 27) that is an indication of rapid lysosomal exocytosis. 
Fig. 26 TFEB stimulates clearance of enlarged lysosomes in PD myotubes. (A) Confocal 
microscopy image of PD myotubes (cl. 3LE8) infected for 72 h with adenovirus containing 
TFEB (PD+Ad-TFEB 72 h) shows a dramatic reduction in the number of large LAMP1-positive 
lysosomes (red) compared to that in untreated (PD) or adenovirus (PD+Ad-null)-treated PD 
myotubes. WT myotubes are shown on the left panel. Nuclei are stained with Hoechst (blue). 
TFEB was detected with anti-Flag antibody (green). (B) Distribution of lysosomal size differs 
significantly in Ad-null and Ad-TFEB PD myotubes (p=6.32x10-8; Kolmogorov–Smirnov test). 
Lysosomal size is expressed as number of pixels representing lysosomal area (LAMP1-positive 
structures). The median lysosomal size of Ad-TFEB infected myotubes (m=367.13 pixels, 
n=703, range 208–2659) was significantly lower than that of Ad-null infected myotubes 
(m=491.16 pixels, n=1395, range 200–2857; p=6.5x10-12; Wilcoxon rank sum test). Bar: 10 µm. 
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In addition we tested the effect of constitutively active mutant TFEB (S211A; 
TFEBmt) [22, 128, 129] in PD myotubes. Massive accumulation of TFEB in the 
nuclei resulted in a striking clearance of large lysosomes without any decrease in the 
total amount of LAMP1 protein (Fig. 29A and B). In fact levels of LAMP1 appear to 
increase in TFEBmt-treated cells, consistently with the observed role of TFEB in 
stimulating lysosomal biogenesis [19, 21]. 
The reduction of enlarged lysosomes in TFEB-treated PD myotubes was associated 
with a significant decrease in the amount of accumulated storage material as shown 
by the incorporation of the fluorescent glucose derivative 2-NBDG in glycogen (Fig. 
28). 
Fig. 27 TFEB induces relocation of lysosomes to the plasma membrane in PD myotubes. 
Confocal microscopy image of PD myotubes infected for 24 h with Ad-TFEB shows 
relocation of lysosomes to the plasma membrane (top). Images showing LAMP1 staining (red) 
on plasma membrane in a PD myotube infected with Ad-TFEB (bottom; arrows) but not in a 
non-infected cell (middle). Non-permeabilized cells were incubated with anti-LAMP1 
antibody at 48C for 40 min, followed by fixation and staining with secondary antibody. Bar: 
10 µm. 
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These data demonstrate the effectiveness of TFEB overexpression in the reduction of 
glycogen storages in PD myotubes.  
Notably TFEB-overexpressing fibres change their morphology; normally elongated 
myotubes become spindle-like and contain centrally located nuclei (Fig. 29). 
However no toxicity was observed, as TUNEL assay revealed only occasional 
apoptotic cells, and no activation of caspase-3 was detected by western blot in the 
same treated fibres (Fig. 30). 
 
 
 
Fig. 28 TFEB reduces glycogen burden in PD myotubes. Confocal microscopy images of live 
non-infected PD myotubes (left) or PD myotubes infected for 72 h with Ad-TFEB (right) show a 
dramatic reduction in the amount of accumulated glycogen in TFEB-treated cells. The cells were 
incubated with the fluorescent glucose (2-NBDG; green), extensively washed, and analyzed 
using confocal microscopy. Bar: 10 µm. 
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2.2 TFEB overexpression in PD muscle induces cellular clearance by promoting 
lysosomal/autophagosomal exocytosis 
Fig. 29 TFEBmt reduces lysosomal size in PD myotubes. (A) Immunostaining of non-
infected cells (day 13 in differentiation medium) and cells infected with a mutant form of 
TFEB (TFEBmt) with LAMP1 (red) and Flag (green). Ad-TFEBmt was added to the 
myotubes for 72 h on day 10 in differentiation medium. Ad-TFEBmt-infected cells show 
massive accumulation of TFEB in the nuclei and significant reduction in lysosomal size, 
similar to that seen with TFEB. (B) Western blot of cell lysates confirms the presence of 
TFEB in the nuclear fraction; the different intensities of the two bands corresponding to 
LAMP1 protein in untreated and TFEBmt-treated samples may reflect the differences in the 
glycosylation pattern. Bar: 10 µm. 
Fig. 30 TFEBmt induces apoptosis in a subset of PD myotubes.  (A) Western blot of protein 
lysates from untreated, Ad-null, TFEB, and TFEBmt-treated myotubes with anti-caspase-3 
antibody. No activated (cleaved) products are detected in any condition. α-Tubulin was used as a 
loading control. (B) TUNEL assay shows the presence of some apoptotic cells in Ad-TFEB-
infected cultures, but not in control cultures infected with adenovirus alone (n=3). Bar: 10 µm. 
 
55 
 
 
To evaluate the effect of TFEB on lysosomal and autophagic pathologies in vivo, 
three knockout mouse strains were used: the previously described GAA -/- and 
autophagy deficient GAA -/- (Atg7:GAA DKO) models [41], and a newly developed 
GFP-LC3:GAA -/- strain. Flexor digitorum brevis (FDB) muscles from each model 
were transfected using electroporation with plasmids containing TFEB and/or 
LAMP1 (Table 1), and live single fibres were analysed four to six days after 
transfection by time-lapse confocal microscopy, or alternatively, live fibres were 
fixed and stained for imaging. 
 
 
 
Both Flag-TFEB/mCherry-Lamp1 and GFP-TFEB/mCherry-Lamp1-transfected PD 
fibres showed a striking decrease in the number of large lysosomes, docking and 
fusion of enlarged lysosomes to the plasma membrane, the emergence of multiple 
normal dot-like size lysosomes (Fig. 31 and 32) and a markedly increased motility 
and fusion of lysosomes (Fig. 33) compared to untreated PD controls. 
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Fig. 31 TFEB promotes clearance of enlarged lysosomes in PD fibres. Confocal 
microscopy images of live fibres derived from 3 to 4 month-old GFP-LC3: WT (top left), 
untreated GFP-LC3:GAA -/- (bottom left) or TFEB-treated GFP-LC3:GAA -/- (right) mice. 
All fibres were transfected with mCherry-LAMP1 to visualize lysosomes (red). The effects of 
TFEB are clearly visible – overall reduction in lysosomal size, appearance of normal size 
lysosomes (similar to those in the WT), and lysosomal docking to the plasma membrane 
(inset). Bar: 10 µm. 
 
 
Fig. 32 TFEB induces lysosomal localization to plasma membrane in PD fibres. FDB 
muscle of a GAA-/- mouse was transfected with both GFP-TFEB and mCherry-LAMP1 
(GAA-/- + GFP-TFEB). Images were taken before (left) and after 4 h (right) of time-lapse 
microscopy. Lysosomal clearance is visible in the TFEB-transfected fibre at both time points. 
Lysosomes appear to ‘‘exit’’ the fibre (inset and arrow) at the 4 h time point when TFEB is 
activated, as evidenced by its nuclear translocation (green nuclei). Bar: 10 µm. 
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Importantly TFEB-transfected fibres showed normal shape and appearance, 
suggesting that overexpression of TFEB does not cause any appreciable muscle 
damage.  
The use of GFP-LC3:GAA -/- strain revealed the lysosomal/autophagosomal fusion 
rate as a possible issue causing autophagic build-up. The expression of mCherry-
LAMP1 was seen almost exclusively in fibres or region of fibres free of autophagic 
build-up (80-90% of all transfected fibres), suggesting a compromised lysosomal 
biogenesis in areas of autophagic accumulation. However in those fibres in which 
mCherry-LAMP1 was expressed in the build-up area (10-20 %), lysosomal-
autophagosomal fusion appear rare or non-existent (data not shown). 
It was reasonable to assume that TFEB overexpression may increase lysosomal-
Fig. 33 TFEB increases lysosomal motility in PD fibres. The mean maximum velocity of 
lysosomes (top) and the number of large (>3.5 mm) lysosomes (bottom) in untreated and TFEB-
treated PD fibres (note: all data for Flag- and GFP-TFEB-treated fibres are pooled). Lysosomal 
velocities were calculated from time-lapse images using ImageJ software with the manual 
tracking plug-in. For each condition the trajectories of multiple lysosomes were followed (n=26 
untreated; n=43 TFEB-treated) and the three highest velocity measurements per lysosome were 
recorded. In TFEB-treated fibres, the maximum velocity of lysosomes was significantly 
increased (p=2.07x10-17) and the number of large lysosomes was significantly decreased 
(p=1.0x10-3). Ten untreated and 24 TFEB-treated fibres were analyzed for the size calculations. 
* indicates statistically significant differences (p≤0.001; Student’s t-test). Error bars represent 
95% confidence intervals. 
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autophagosomal fusion, which would thus prevent or resolve autophagic build-up in 
PD muscle. To analyse the effects of TFEB on lysosomal-autophagosomal fusion we 
performed time-lapse microscopy on live GFP-LC3:GAA -/- fibres transfected with 
both TFEB and LAMP. We observed an increased co-localization between LAMP1 
(red) and LC3 (green) in TFEB treated fibres (Fig. 34A and B) and a clear alignment 
of doubly labelled autophagolysosomes along the plasma membrane (Fig. 34B). This 
suggests that TFEB may induce lysosomal/autophagosomal exocytosis. These data 
raised the intriguing possibility that autophagy may facilitate TFEB-induced 
lysosomal clearance. 
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2.3 Suppression of autophagy attenuates TFEB-mediated cellular clearance in 
PD muscle 
Fig. 34 TFEB stimulates lysosomal-autophagosomal fusion and clearance. Confocal 
microscopy images of live fibres from GFP-LC3:GAA-/- mice. (A) Muscle was transfected 
with mCherry-LAMP1 only. The image (a single frame from the time-lapse series presented in 
Movie 5) shows lysosomes (red), LC3-positive autophagosomes (green) and a number of 
autolysosomes (yellow). (B) Muscle was transfected with Flag-TFEB and mCherry-LAMP1. 
Massive formation of autolysosomes is indicated by yellow structures; the three lower panels 
provide a snapshot of the process of exocytosis. The structures at the plasma membrane are 
labelled with both LC3 and LAMP1, indicating that they represent amphisomes (a product of 
fusion between autophagic vesicles and late endosomes) or autolysosomes (a product of fusion 
between autophagic vesicles and lysosomes). Bar: 10 µm. 
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To address the role of autophagy in TFEB-mediated cellular clearance, GFP-TFEB 
and mCherry-LAMP1 were transfected into muscle-specific autophagy-deficient 
GAA -/- mice (Atg7:GAA DKO). All the signs of TFEB effects on lysosomal 
pathology were observed: size reduction, redistribution and docking along the plasma 
membrane (Fig. 35B), while no effects on lysosomal movement and fusion were 
observed when autophagy was suppressed. The maximum velocity of lysosomes was 
significantly lower than that in TFEB-treated PD mice (Fig. 36). Furthermore the 
TFEB-induced cellular clearance was lower in TFEB-treated autophagy deficient 
muscles than in controls, as indicated by a slight decrease in the number of large 
lysosomes (Fig. 36, bottom). This limited effect is particularly striking given the 
already decreased baseline lysosomal size (Fig. 35A and Fig.36) and a previously-
reported reduction of glycogen levels in autophagy-deficient PD muscle [130].  
Altogether these data suggest that autophagy is a prerequisite for efficient TFEB-
mediated cellular clearance. 
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Fig. 35 TFEB promotes redistribution and docking of lysosomes to the plasma membrane 
in autophagy-deficient PD fibres. Confocal microscopy images of live fibres from muscle-
specific autophagy-deficient GAA-/- mice (Atg7:GAA DKO). (A) Muscle was transfected with 
mCherry-LAMP1 only. (B) Muscle was transfected with GFP-TFEB and mCherry-LAMP1 
(Atg7:GAA DKO + GFP-TFEB). The TFEB-transfected fibres show realignment of the 
lysosomes and membrane detachment (most striking in top and bottom panels) similar to those 
in TFEB-transfected fibres from PD mice (see Fig 32 inset). Lysosomes can be seen in the 
space between the fibre and plasma membrane (arrows). Bar: 10 µm. 
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2.4 Intramuscular injection of AAV 2.1-TFEB results in clearance of glycogen 
stores and amelioration of muscle pathology 
 
We tested the effect of TFEB overexpression on muscle pathology in vivo by direct 
intramuscular injection of AAV 2.1-TFEB vectors in PD mice. Mice were injected at 
1 month of age in three sites of the right gastrocnemius muscle, while the left 
gastrocnemius was injected with AAV 2.1-GFP vector and used as un-injected 
control. The animals were sacrificed 45 days after injection to allow maximal, 
sustained expression of the vector. Levels of TFEB, analysed by Real-Time PCR, 
were 10-fold higher in the AAV 2.1-TFEB injected muscles compared to those in 
controls. 
Fig. 36 TFEB increases lysosomal velocity in autophagy-deficient PD fibres. The mean 
maximum velocity of lysosomes (top) and the number of large (>3.5mm) lysosomes (bottom) 
in untreated and TFEB-treated autophagy-deficient Atg7:GAA DKO fibres. The increase in 
maximum velocity (41%) is significant (p=2.729x10-18; n=57 lysosomes for untreated; n=52 
lysosomes for TFEB-treated), but there is only a slight trend toward smaller lysosomal size 
(p=7.0x10-2; n=10 fibres for untreated; n=21 fibres for TFEB-treated). The corresponding 
values from GAA-/- mice are presented for comparison (for TFEB-treated condition: n=19 
lysosomes for velocity measurements, and n=10 fibres for the lysosomal size measurements).  
* indicates statistically significant differences (p≤1.0x10-5 for the top panel and p≤0.01 for the 
lower panel; Student’s t-test). 
63 
 
TFEB expression resulted in near-complete clearance of accumulated glycogen (Fig. 
37).  
 
 
 
 
The reduction of glycogen stores in TFEB-treated muscles was also confirmed by 
PAS staining (Fig. 38) and by a decrease in the size of LAMP1 positive vesicles (Fig. 
39). 
 
 
 
 
 
Fig. 37 Intramuscular injection of AAV2.1-TFEB in GAA -/- mice promotes glycogen 
clearance. Glycogen assay in TFEB-injected gastrocnemii and in the contralateral muscles. In 
TFEB-injected muscles glycogen levels were significantly decreased compared to those in 
untreated muscles. * indicates statistically significant differences (p=1.0x10-4; n=6; Student’s 
t-test). 
Fig. 38 Intramuscular injection of AAV2.1-TFEB in GAA -/- mice attenuates PD 
pathology. PAS staining of TFEB-treated muscle shows a reduction of lysosomal glycogen 
stores (puncta) compared to those in untreated muscle. Original magnification: 20x. 
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In addition we performed a more precise structural analysis of the 
autophagosomal/lysosomal compartment in TFEB treated muscle by EM analysis and 
found a significant improvement of muscle ultrastructure after TFEB overexpression. 
Specifically we observed a clear reduction in size and number of glycogen-containing 
lysosomes compared to those in PD muscle (Fig. 40A and B, left and middle panels). 
Furthermore, the intra-lysosomal electron-dense glycogen particles seen in untreated 
fibres (Fig. 40A, bottom left, asterisk) showed looser organization in TFEB-treated 
muscle (Fig. 40A, bottom right, asterisk). 
In addition we observed an increased number of autophagosomes in close proximity 
to glycogen-containing organelles in TFEB-treated muscle (Fig. 40A bottom right, 
black arrows; Fig. 40B right panel). Moreover lysosomes frequently contained 
remnants of other intracellular organelles in their lumens (Fig. 40A bottom right, 
empty arrow), indicating active fusion with neighbouring autophagosomes. 
The number of mitochondria in TFEB-treated fibres was comparable to that in 
untreated PD mice, and the size and morphology of mitochondria were normal (Fig. 
Fig. 39 Intramuscular injection of AAV2.1-TFEB in GAA -/- mice promotes 
clearance of enlarged lysosomes. LAMP1 staining of TFEB-injected gastrocnemii and of 
the contralateral untreated muscles. In TFEB-treated muscles, the size of LAMP1-positive 
vesicles was reduced. Bar: 2 µm. 
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40C). 
These data on intramuscular injection indicate that TFEB is able to significantly 
rescue glycogen storage and morphological abnormalities. 
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Fig. 40 Impact of TFEB on muscle fibre ultrastructure in GAA -/- mice. (A) EM images of 
muscle injected with either AAV-GFP (untreated) or AAV-TFEB (TFEB-treated). Asterisks 
indicate glycogen-containing lysosomes. Bar: 1.5 µm (upper panels) and 0.45 µm (lower panels). 
Higher magnification images (lower panels) show that glycogen particles are less densely packed 
in TFEB-treated muscle. Black arrows indicate autophagosome profiles; the white empty arrow 
shows remnants of mitochondria engulfed by the lysosome. (B) Graphical presentations of 
lysosomal length (average ± SE; n=100 lysosomes; p=6.31x10-5), the number of lysosomes per 5 
mm2 area of muscle fibre section (average ± SE; n=50 fields; p= 4.80x10-3), and the number of 
autophagosomes flanking glycogen-containing lysosomes (average ± SE; n=100 lysosomes; 
p=4.39x10-5 <0.001). Student’s t-test was used for each comparison. (C) Graphical presentations 
of mitochondrial size (average ± SE; n=100) and the number of mitochondria per 5 mm2 area of 
muscle fibre section (average ± SE; n=50 fields). The differences were not significant by 
Student’s t-test (p=3.65x10-1 and 4.27x10-1, respectively). 
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DISCUSSION 
 
In the first part of my PhD work I contributed to the identification of a specific 
pathway leading to cellular pathology in Lysosomal Storage Disorders, while in the 
second part of my PhD I used the knowledge derived from the previous work to 
develop a therapeutic approach for the treatment of LSDs. 
In particular we demonstrated that in LSDs, secondary cholesterol accumulation 
causes a change in the endolysosomal membrane’s organization and severely reduces 
the ability of lysosomes to efficiently fuse with other membranes. Specifically we 
showed that these cholesterol-dependent abnormalities cause defects in the fusion of 
lysosomes with endosomes and autophagosomes in two models of LSDs. We propose 
that this may represent a common early pathogenic mechanism underlying the 
endocytic jam observed in these disorders. Anyway there is still the need to clarify 
how the lysosomal primary defect leads to cholesterol accumulation, although some 
connections between these two pathogenic events have been identified in some LSDs 
[131, 132]. 
Our study also demonstrates that cholesterol accumulation in endolysosomal 
membranes impairs SNARE function. Physiological cholesterol-dependent clustering 
of SNAREs is implicated in defining the exocytotic sites on the plasma membrane in 
specialized secretory cells and in facilitating the exocytosis of synaptic vesicles [13, 
113, 115, 116]. Moreover cholesterol has been shown to bind to synaptotagmin and 
promote synaptic vesicle biogenesis [112]. We argue that deleterious effects of 
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cholesterol accumulation in LSD membranes may result from the functional 
interaction of cholesterol with the SNARE apparatus. 
In fact we demonstrate that endolysosomal cholesterol levels affect the membrane 
distribution of post-Golgi SNAREs involved in the fusion of lysosomes with 
endosomes and autophagosomes. Cholesterol accumulation in LSDs cells, and in 
cholesterol-loaded WT cells, induces SNAREs aggregation in cholesterol-enriched 
microdomains of endolysosomal membranes, resulting in the trapping of SNAREs in 
assembled complexes, and thus in a slower rate of SNARE recycling. Remarkably a 
previous study showed that the increase in cholesterol-enriched regions on plasma 
membranes inhibits SNARE function in exocytosis [133]. Cholesterol-dependent 
SNARE dysfunction may result from cholesterol’s inhibition of SNARE dynamics in 
the endolysosomal membrane, a compartment normally deprived of cholesterol. This 
may in turn prevent SNAREs from correctly interacting with components of the 
fusion-recycling machinery. This hypothesis is supported by previous studies which 
demonstrated that cholesterol-mediated sub-compartmentalization of the lysosomal 
membrane protein LAMP-2A negatively affects chaperone-mediated autophagy 
[134]. 
In summary, in the first part of my PhD, I showed that cholesterol abnormalities in 
LSDs determine lysosomal fusion deficiency by affecting proper SNARE function. 
We identified lysosomal dysfunction, due to cholesterol accumulation, as a possible 
pathogenic mechanism causing cellular damage and death in LSDs. From this 
discovery we aimed to positively modulate lysosomal compartment in order to obtain 
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cellular clearance in LSDs. We also took advantage of our lab’s discovery of TFEB 
as a transcription factor that positively regulates lysosomal biogenesis and function 
[19]. We also showed that TFEB triggers lysosomal exocytosis and promotes cellular 
clearance in cellular models of LSDs [101]. From these discoveries we speculated the 
effectiveness of TFEB over-expression to increase lysosomal functions, prevalently 
lysosomal exocytosis, in order to obtain cellular clearance in an in vivo model of 
Pompe Disease. 
We showed that TFEB efficiently triggers lysosomal exocytosis and promotes 
cellular clearance in muscle cells, isolated live muscle fibres and the whole muscle of 
PD mice. 
The process of lysosomal exocytosis was initially ascribed to a subset of secretory 
lysosome, called lysosome-related organelles, which reside in particular cell types, 
such as haematopoietic cells or melanocytes [135]. Recently it has been shown that 
also conventional lysosomes can undergo fusion with plasma membrane and 
exocytosis [11] in a Ca2+ dependent process regulated by synaptotagmin. The process 
of conventional lysosome exocytosis is considered to be critical for the repair of 
plasma membrane lesions [136]. 
In addition lysosomal exocytosis has been implicated in mediating cellular clearance 
in cell models of several LSDs, such as metachromatic leukodystrphy and 
mucolipidosis type I [137]. Furthermore it has been shown that lysosomal exocytosis 
is the mechanism by which 2-hydroxypropyl-β-cyclodextrin – an approved drug for 
yet another LSD, Niemann Pick type C (NPC) disease - alleviates cholesterol storage 
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in NPC cells [138]. 
Lysosomal exocytosis became an interesting therapeutic opinion for LSD after the 
discovery of TFEB [21, 101, 139]. Overexpression of TFEB induced lysosomal 
exocytosis in a mouse model of MSD and in cells derived from the murine models of 
MPS-IIIA, neuronal ceroid lipofuscinoses and MSD [101]. 
In the second part of my PhD I also helped demonstrate the positive effects of TFEB 
overexpression on cellular clearance in terminally differentiated multinucleated 
muscle cells and PD muscles. Specifically we showed that the hallmarks of PD 
(number of large glycogen-filled lysosomes and the amount of accumulated 
glycogen) were significantly reduced in both cultured myotubes and muscle fibres 
after TFEB overexpression, thus providing strong evidence of TFEB potential as a 
therapeutic target for PD. 
In TFEB-treated myotubes the lysosomal marker LAMP1, that is typically present 
inside the cells, was seen on the outer plasma membrane. In addition we also showed 
a potential problem with high TFEB activity, as the expression of a constitutively 
active form of TFEB (TFEB S211A) invariably resulted in morphological changes of 
myotubes, perhaps because of massive expulsion of lysosomes. 
Time-lapse confocal microscopy experiments on live fibre allowed us to track 
lysosomal movements and fusion in order to estimate the motility of lysosomes and 
to examine the interactions between lysosomes and autophagosomes after TFEB 
overexpression. Similarly to what we observed in the cellular system, we found that 
TFEB efficiently triggered lysosomal exocytosis and promoted cellular clearance. 
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The development of a new PD mouse model, the GFP-LC3:GAA -/- strain, allowed 
us to address the effects of TFEB on autophagic accumulation. In fact defects in 
autophagy, a major lysosome-dependent degradative system, significantly contribute 
to the pathophysiology of several LSDs [95, 99, 100, 140]. In PD skeletal muscle, the 
autophagic defect is particularly striking, manifesting as a massive build-up that 
poses an additional problem for ERT. 
Remarkably none of the TFEB-transfected fibres showed areas of autophagic build-
up, which are so prominent in most non-transfected PD fibres. This condition 
suggests that TFEB may have rescued autophagic function in PD muscle. TFEB–
treated fibres exhibited a significant increase in fusion between LC3 and LAMP1 
positive vesicles, the appearance of multiple LC3/LAMP1-positive 
autophagolysosomes and docking of these double-positive structures to the plasma 
membrane. Altogether these data suggest that TFEB may rescue autophagy by 
stimulating the formation and secretion of autophagolysosomes, a product of 
lysosomal-autophagosomal fusion. 
In fact we hypothesized that lysosomal exocytosis mediating cellular clearance in our 
model may be a process involving autophagy and secretion of autophagolysosomes. 
This hypothesis is supported by the attenuated effect of TFEB on lysosomal velocity 
and clearance observed in autophagy-deficient PD mice. 
Moreover the absence of lysosomal-autophagosomal fusion and low expression of 
LAMP-1 in the build-up area suggest inefficient local lysosomal biogenesis. LAMPs 
are considered to be of key importance for lysosomal movement, maturation of 
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autophagosomes and lysosomal exocytosis [141]. Therefore, these low local LAMP1 
concentrations in the build-up area may have far-reaching consequences. The build-
up process appears to begin with the failure of a subset of lysosomes to fuse with 
autophagosomes, perhaps because of lysosomal rupture during muscle contractions. It 
is possible that this fusion defect and the paucity of the newly-formed lysosomes 
create conditions that favour expansion of the autophagic build-up. With the capacity 
to resolve both of these deficits by promoting lysosomal-autophagosomal fusion and 
biogenesis, TFEB is uniquely suited to remedy autophagic and lysosomal pathologies 
in PD. 
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MATERIALS AND METHODS 
 
1 Lysosome isolation 
 
Lysosomes were isolated from MEFs by magnetic chromatography using the two-
step elution protocol described in [102]: Subconfluent 150 x 25-mm dishes were 
treated for 9h with FeDex medium at 37°C and subsequently maintained in normal 
Dulbecco’s Modified Eagle medium (DMEM) for 16h. Cells were then collected by 
trypsin treatment, washed in buffer A (250 mM sucrose in 4 mM imidazole/HCl 
buffer pH 7.4) and then re-suspended in 750 µL of Buffer A+ (buffer A with the 
addition of 5 mM iodoacetamide and protease inhibitors). Plasma membranes were 
split by forcing cells twice through an 18G needle and five times through a 26G 
needle, and then the nuclei and broken membranes were pelleted by centrifugation at 
600g for 5 min. The post-nuclear supernatant (PNS) was loaded on a MiniMACS 
column previously equilibrated with 10 mL of Buffer A and with the magnet 
attached. The unbound material was collected by gravity flow (flow-through) and the 
column washed with 10 mL of TBS (150 mM NaCl, 5 mM Tris-HCl pH 7.4). 
Lysosome were broken by applying an hypotonic buffer B (5 mM Tris-HCl with the 
same protease inhibitor concentration as in buffer A+) and luminal proteins were 
eluted by gravity flow. Finally lysosomal membrane proteins were eluted by 
removing the magnet and adding a hypotonic buffer B+1% Triton X-114. 
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2 GP analysis and sucrose gradients 
 
The GP analysis was performed following the protocol described in [108]: lysosomal 
membranes were stained for 15 min with 100 nM C-laurdan. Samples were excited at 
385 nm, and emission spectra were recorded from 400 to 530 nm. Spectra of 
unstained samples were subtracted from the sample labelled with C-laurdan. The GP 
values were calculated according to following formula: GP= I400-460-I470-530/I400-
460+I470-530, where I400-460 and I470-530 are the total fluorescence intensities recorded 
from 400 to 600 nm and from 470 to 530 nm, respectively. 
For sucrose gradients, solubilised lysosomal membrane proteins were loaded at the 
bottom of a 9-mL discontinue sucrose gradient (40, 35, 30, 25, 20 15, 10 and 5%) in 
TNE (50 mM Tris-HCl pH 7.4, 150 mM NaCl and 5 mM EDTA) with the addition of 
1% Triton X-114. Samples were ultracentrifuged at 39000 r.p.m. for 19 h at 4°C, and 
then 12 aliquots of 750 µL (corresponding to DRMs, intermediate and soluble 
fractions) were collected from the top to the bottom of the gradient and processed for 
cholesterol content, protein concentration and immunoblot analysis. Protein 
concentration was determined using the Dc Protein Assay kit (Bio-Rad). For 
immunoblot analysis, proteins from collected gradient fractions were precipitated in 
methanol/chloroform, resuspended in Laemmli buffer and subjected to SDS-PAGE to 
be probed with specific antibodies. Densitometry quantification of immunoblotted 
membranes was performed using the ImageJ program. 
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3 Phospholipid and cholesterol assay 
 
Total lipids were purified by lysosomal membrane samples with a two-step Bligh and 
Dyer lipid extraction protocol. Dried lipids were suspended in methanol-chloroform 
(1:2) and then resolved on a TLC plate (Silica gel 60, MERCK). The developing 
solvent was methanol:chloroform:ammonia (65:35:5). Phospholipids and cholesterol 
were detected by Molybdenum blue staining (Sigma). 
Phospholipids were quantificated with a phosphate assay protocol: purified lipids 
were incubated 1h at 190°C with perchloric acid. After addition of ammonium 
molybdate (1%) and ascorbic acid (4%) the samples were incubated at 37°C for 2h. 
The amounts of phospholipids in each sample were calculated by reading absorbance 
at 800 nm. 
Cholesterol content was determined using the Amplex Red Cholesterol Assay kit 
(Invitrogen) by following the manufacturer’s protocol. 
 
4 Antibodies 
 
The following antibodies were used: rabbit polyclonal anti-LAMP1 (Sigma), rat 
monoclonal anti-Lamp1 (Santa Cruz Biotechnology), mouse monoclonal anti-Vti1b 
(BD Bioscences), rabbit polyclonal anti-Vti1b (Synaptic System), mouse monoclonal 
anti-SNARE TI VAMP1 1C7 (a kind gift from T. Galli, INSERM U950, Paris, 
France), mouse monoclonal anti-Flotillin (BD Bioscences), mouse monoclonal anti-
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transferrin receptor (Zymed), rabbit polyclonal anti-GFP (Abcam), rabbit polyclonal 
anti-EpsinR (a kind gift from DJ Owen[121]), rabbit polyclonal anti-golgin 97 (a kind 
gift from AM De Matteis, TIGEM, Italy), rabbit polyclonal anti-SNAP23 (Synaptic 
System), rabbit polyclonal anti-Syntaxin 5 (Synaptic System), mouse monoclonal 
anti-α/β-SNAP (Synaptic System), anti-Sec22 (a kind gift from AM De Matteis, 
TIGEM, Italy), rabbit polyclonal anti-Rab7 (Abcam), rabbit polyclonal anti-EGFR 
(Santa Cruz Biotechnology) and rabbit polyclonal anti-cholera toxin B (Vibrant Lipid 
Rafts Labelling Kit, Molecular Probe), mouse anti-cytochrome (BD Bioscience), 
mouse anti-MyoD (BD Bioscience), mouse anti-Flag M2 (Sigma), mouse anti-
myogenin (Dako), mouse anti-myosin heavy chain (Clontech), rabbit anti-Histone H3 
(Cell Signalling) and rabbit anti-alpha tubulin (Abcam). Secondary horseradish 
peroxidase-conjugated antibodies (Pierce ECL), secondary antibodies for 
immunofluorescence were conjugated to Alexa Fluor dye 488 or 594 and 633 
(Molecular Probes). 
 
5 Transfections and drug treatments 
 
MEFs were maintained in DMEM supplemented with 10% FBS and 
penicillin/streptomycin (normal culture medium). Sub-confluent MEFs were 
transfected using LipofectamineTM 2000 (Invitrogen) according to manufacturer’s 
protocols. Drug treatments were performed as follows: MβCD (Sigma) at the final 
concentration of 10 mM in normal culture medium for 30 min at 37°C; water-soluble 
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cholesterol (MβCD-complexed cholesterol, Sigma) at the final concentration of 50 
µg/mL in normal culture medium for 90 min at 37°C; Bafilomycin A1 (Upstate) at 
final concentration of 200 nM in normal culture medium for 15h; and EGF (Sigma) at 
the final concentration of 100 mg/mL in normal culture medium for various time 
points (as indicated in Fig. 1). 
 
6 Analysis of SNARE complexes 
 
Purified lysosomal membrane samples in Triton X-114 were centrifuged at 15000 g 
(30 min at 4°C) to isolate the Triton-insoluble material (DRM fraction) and the 
Triton-soluble membrane proteins (soluble fraction). Both fractions together, with 
samples containing the total lysosomal membranes, were treated with Laemmli buffer 
and then divided in two aliquots. One aliquot was boiled (5 min at 100°C) to disrupt 
SDS complexes, whereas the other was kept at 4°C (non-boiled samples) before 
being subjected to SDS-PAGE. 
Densitometry quantification of monomeric and complexed form of Vti1b was 
performed using the ImageJ program. 
 
7 Immunoprecipitation 
 
Cells were washed in PBS, and a post-nuclear supernatant was obtained by scraping 
cells in isotonic buffer and centrifuging them at 5000 g for 5 min. One volume of 2x 
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lysis buffer (50 mM Tris-HCl pH7.9, 200 mM NaCl, 1% Triton X-114, 1 mM EDTA, 
50 mM HEPES and protease inhibitors from Sigma) was added to one volume of the 
supernatant, and the samples were then incubated with protein A Sepharose (Sigma) 
overnight, followed by 3h incubation with anti Vti1b antibodies (rabbit polyclonal). 
The immunoprecipitate was separated by centrifugation, boiled in Laemmli buffer 
and loaded onto 5-10% SDS-PAGE. 
 
8 Plasmids 
 
For the GFP-Vti1b plasmid construction, the corresponding amplified cDNA was 
cloned in the pEGFP-C3 vector (Clontech). The GFP-VAMP7 was a kind gift of M. 
D’Esposito (IGB, Naples, Italy). The GFP-GPI was a kind gift from J. Lippincott-
Schwartz (NICHD, NIH, Bethesda, MD, USA). The tandem-fluorescent-LC3 
(mRFP-GFP-LC3) plasmid was a kind gift from T. Yoshimori [1]. 
The plasmid containing the full-length 3xFlag-tagged human TFEB (referred to as 
Flag-TFEB) was described previously [19]. The plasmid containing the full-length rat 
Lamp1 (mCherry-Lamp1) was a kind gift of K. Zaal (Light Imaging Section, Office 
of Science and Technology, NIAMS, NIH, Bethesda, MD, USA). The plasmid 
containing GFP-TFEB was described previously [128]. 
 
9 Immunofluorescence analysis 
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Cells were washed three times in cold PBS and then fixed in 4% paraformaldehyde 
(PFA) for 15 min. Fixed cells were washed four times in cold PBS, permeabilized 
with 0.1% Saponin in blocking solution (0.5% BSA, 50 mM NH4Cl and 0.02 NaN3 in 
PBS) for 30 min and immunolabelled with appropriate primary and secondary 
antibodies. Cells were then washed four times in cold PBS and mounted in 
Vectashield mounting medium.  
For dextran-Lamp1 co-immunofluorescence, cells were loaded with 100 µg/mL 
dextran (10000 MW) conjugated with the Alexa Fluor 594 dye (Molecular Probes) 
for 2h, then the dextran was removed and after additional 3h MEFs were fixed in 4% 
PFA and subjected to immunostaining with LAMP1. 
Lipid raft immunofluorescence was performed using the Vibrant Lipid Rafts 
Labelling Kit (Molecular Probes) according to manufacturer’s protocols. 
Confocal microscopy was performed with a Zeiss LSM 510 microscope equipped 
with a Zeiss confocal-scanning laser using an x63 1.4 numerical aperture objective. 
The percentage of co-localizing fluorescence (merge) was quantified by using the 
“co-localization” module of the LSM 3.2 software (Zeiss). 
For immunofluorescence on myotubes, cells were fixed in 2% paraformaldehyde 
(Electron Microscopy Sciences) for 15 min at room temperature, washed twice in 
PBS and permeabilized in 0.2% Triton X-100 (Sigma-Aldrich). Immunostaining with 
LAMP1, LC3 and Flag antibodies was done using M.O.M kit (Vector Laboratories) 
as described in [38]. The cell nuclei were stained with 2µg/mL Hoechst 33342 (Life 
Technologies) in PBS for 10 min. After staining, the cells were imaged on a Carl 
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Zeiss LSM 510 confocal microscope with a 40x or 63x oil immersion objective. 
 
10 Immuno-electron microscopy 
 
For EM on cells: MEFs transfected with GFP-VAMP7, GFP-GPI or treated with 
cholera toxin B (according to manufacturer’s protocols of Vibrant Lipid Rafts 
Labelling Kit, Molecular Probe) to target GM1 ganglioside (a raft lipid), were 
washed with PBS and fixed in a solution of 4% PFA and 0.1% glutaraldehyde in 
0.2M HEPES buffer (pH 7.4) for 15 min at room temperature, and then for additional 
30 min in 4% PFA alone. After washing with PBS, cells were incubated for 30 min in 
blocking solution (50 mM NH4Cl, 0.1% Saponin and 1% BSA in PBS) and overnight 
at 4°C with either anti-GFP or anti-cholera toxin B antibody diluted 1:100 in 
blocking solution. Cells were washed and incubated for 1h at room temperature with 
Nanogold-conjugated anti-rabbit IgG Fab fragment diluted 1:100 in blocking solution 
and processed according to the Nanogold enhancement protocol (Nanoprobes, 
Yaphank, NY, USA). Stained cells were embedded in Epon-812 and cut. The EM 
images were acquired from thin sections using an FEI Tecnai-12 electron microscope 
equipped with an ULTRA VIEW CCD digital camera (FEI, Eindhoven, The 
Netherlands). 
For EM on muscles: muscle tissue was fixed in 1% glutaraldehyde in 0.2 M HEPES 
buffer and post-fixed in uranyl acetate and OsO4. After dehydration through a graded 
series of ethanol and propilenoxide, the tissue was embedded in the Epoxy resin 
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(Epon 812, Sigma-Aldrich) and polymerized at 60°C for 72h. EM images of thin 
sections were acquired using a FEI Tecnai-12 electron microscope (FEI, Einhoven, 
The Netherlands) equipped with a VELETTA CCD digital camera (Soft Imaging 
Systems GmbH, Munster, Germany). Quantification of the number of lysosome-like 
organelles and their dimensions, as well as the number of autophagosomes, was 
performed in 50 fields (of 5µm2 dimensions) distributed randomly through the thin 
sections containing different fibres. 
 
11 EGFR endocytosis 
 
For EGFR endocytosis analysis, MEFs were starved in DMEM without the addition 
of FBS for 19h. After starvation, cells were treated with EGF to stimulate EGFR 
endocytosis. Cells were then collected at various time points (as indicated in Fig. 1) 
and lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 1% Triton X-100, 150 mM NaCl, 
1 mM EDTA and 0.1% Na deoxicholate) with protease inhibitor (Sigma). Protein 
extracts were subjected to SDS-PAGE and immunoblotted using anti-EGFR 
antibody. 
 
12 Analysis of autophagic flux 
 
To monitor autophagic rate, MEFs were transfected with mRFP-GFP-LC3 that 
showed a GFP and RFP signal before the fusion with lysosomes. Only the the RFP 
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signal after fusion was exhibited due to the loss of GFP fluorescence within the acidic 
lysosomal environment. After 33h, cells were treated with bafilomycin for 15h to 
block lysosome-autophagosome fusion. After the removal of Bafilomycin from the 
culture medium the extent of lysosome-autophagosome fusion was evaluated after 1 
and 3h by fixing in 4% PFA and measuring the green/red fluorescence ratio (GFP 
loss) in the regions corresponding to the vesicles, using a homemade MATLAB (The 
Mathworks) application (F. Formiggini). 
 
13 FRAP analysis 
 
For FRAP experiments, EGFP-Vti1b was transfected in MEFs cells grown on glass-
bottomed microwell dishes (Mat-Tek). An area containing EGFP-Vti1b-positive 
endolysosomal clusters was photobleached with 100% of the argon laser power at 
488 nm, resulting in a 70-80% reduction in the fluorescence intensity. The long-range 
motility of these groups of organelles was negligible. The recovery of fluorescence 
was monitored over time (300s) by scanning the bleached area at the conventional 
(low) laser power to minimize photobleaching during sampling. To analyse the rate 
of recovery, we compared the fluorescence of the photobleached area to that of an 
adjacent unbleached area of the same cell with similar fluorescence intensity. For 
each time point, the fluorescence of the bleached area was normalized to that of the 
corresponding control (unbleached) area to compensate for possible drift of the focal 
plane or photobleaching incurred during the low light sampling. For each 
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experimental FRAP curve, the t1/2 value was calculated by fitting the data with the 
Boltzmann function. The FRAP experiments were performed at 37°C on Zeiss LSM 
510 microscope equipped with a Zeiss confocal-scanning laser using a x63 1.4 
numerical aperture objective 
 
14 Isolation of single live myofibres 
 
Isolation of single live myofibres from gastrocnemius and extensor digitorum longus 
(EDL) muscle from 3 to 4 month-old mice were isolated as described in [142]. 
Isolation of single live fibres from FDB muscle was done with the protocol described 
in [38]. Live fibres were either monitored by time-lapse microscopy or used for 
labelling acidic organelles (LysoTracker Red DND-99 100 nM, Life Technologies) or 
mitochondria (MitoTracker Red CMXRos 100 nM, Life Technologies). Alternatively 
fibres were fixed in 2% paraformaldehyde for 30 min and immunostained with anti-
cytochrome c and anti-LAMP1 antibodies.  
Live and fixed fibres were analysed on a LSM 510 confocal microscope (Carl Zeiss, 
Germany) equipped with Plan-Neofluar 40x oil immersion objective. 
 
15 In vivo electroporation of skeletal muscle  
Electric-pulse mediated transfer into FDB muscle was performed as described in 
[143]. Animals were sacrificed 4-6 days after the procedure. Live FDB fibres were 
isolated and analysed by time-lapse confocal microscopy.  
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16 Fibroblast and myoblast culture systems 
 
Immortalized PD cell lines were derived from immortoGAA-/- and immortoGFP-
LC3:GAA-/- mice. Single fibres from EDL muscle of 3-4 month-old mice were 
plated in each well (10 fibres per well) of a Matrigel-coated six-well plate in plating 
medium (10% horse serum in DMEM, 0.5% chick embryo extract, and 1x P/S/L-
Glutamine) at 37°C, 5% CO2. After 3 days, when the satellite cells began to migrate 
away from fibres, most of the medium (3/4) was replaced with proliferation medium 
(20% foetal bovine serum, 10% horse serum, 1% chick embryo extract, 1x P/S/L-
glutamine in high glucose DMEM). Myogenic colonies were isolated with cloning 
cylinders (Corning) on day 5 or 6. Several individual myogenic clones were isolated 
and analysed for their proliferation capacity and the ability to differentiate into 
myotubes. To induce the expression of H-2Kb-tsA58 SV40 large T-antigen for 
immortalization of the satellite cells and myoblasts, recombinant IFN-γ (Life 
Technologies) was added to the proliferation medium (100 units/mL). The cells were 
then incubated at 33°C in an atmosphere of 5% CO2. When myoblasts became nearly 
confluent, the medium was changed to differentiation medium (DMEM containing 
2% horse serum, 0.5% chick embryo extract, 1x P/S/L-glutamine), and then the cells 
were moved to 37°C in an atmosphere of 5% CO2. Myotubes began to form within 2 
days. Glucose concentration was either 1 g/L (low) or 4.5 g/L (high). Myotubes 
survived in culture for 2-3 weeks. A wild type immortalized muscle cell line served 
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as the control. 
 
17 Infection of myotubes with adenovirus expressing TFEB 
 
Adenoviruses expressing either WT or mutant (S211A) TFEB were described 
previously [128]. Myotubes were infected with either adenovirus (Ad-null) or 
adenovirus expressing WT TFEB (Ad-TFEB) or S211A TFEB (Ad-TFEBmt) for 24, 
48 or 72h.  
 
18 Fluorescent glycogen detection, LDH measurements, in situ detection of 
apoptotic cells, surface LAMP1 analysis and acid phosphatase assay 
 
Lysosomal glycogen in live cells was detected by the incorporation of 2-NBDG, a D-
glucose fluorescent derivative (2-deoxyglucose), into glycogen as described in[144].  
The amount of LDH released into the medium was assayed using the LDH-
Cytotoxicity Assay Kit II (Abcam) according to the manufacturer’s protocol.  
Apoptotic cells were detected with TUNEL using the ApopTag® fluorescent Direct 
In Situ Apoptosis Detection Kit (Millipore). 
Lysosomal exocytosis in TFEB-treated cell cultures was evaluated by the surface 
LAMP1 assay as previously described [101] and by the measurement of acid 
phosphatase released into the medium. The acid phosphatase assay was performed in 
cultures treated with Ad-TFEB for 2 days according to the standard procedure. 
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19 Western Blot on myotubes and muscle tissues 
 
Myotubes or muscle tissues were homogenized in RIPA buffer (PBS containing 1% 
NP-40, 0.5% sodium deoxycholate, 0.1% SDS and protease/phosphatase inhibitor 
cocktail (Cell Signalling Technology)) and centrifuged for 30 min at 13000 rpm at 
4°C. Alternatively, for nuclear/cytosolic fractionation, cells were lysed in 0.5% 
Triton X-100 buffer (50 mM Tris-HCl, 0.5% Triton X-100, 137.5 mM NaCl, 10% 
glycerol, 5 mM EDTA and protease and phosphatase inhibitors) and centrifuged at 
3000 rpm at 4°C for 5 min. The supernatant constituted the cytosolic fraction. The 
pellet was then washed with 0.5% Triton X-100 buffer, re-suspended in Triton X-100 
buffer with 0.5% SDS, sonicated, and centrifuged at 13000 rpm for 15 min at 4°C. 
The supernatant constituted the nuclear fraction. Protein concentrations were 
measured using the Bio-Rad Protein Assay (Bio-Rad Laboratories). Western blots 
were performed according to standard procedures. 
 
20 Intramuscular injection of AAV-TFEB, muscle staining and glycogen assay 
 
Six 1-month-old GAA -/- mice were injected with a total dose of 1011 GC of AAV 
2/1 TFEB vector preparation into three sites of the right gastrocnemius (three 
injections of 30 µL each) using a Hamilton syringe. Equivalent doses of AAV 2/1 
CMV-EGFP or equal volumes of PBS were injected into the controlateral muscle. 
Animals were sacrificed 45 days after injection and perfused with PBS. 
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Gastrocnemii, free from neighbouring muscle and connective tissue, were isolated 
and analysed. Part of the sample was used to test the levels of TFEB expression by 
RT-PCR. For morphologic analysis, muscles were frozen in liquid nitrogen-cooled 
isopentane. Immunostaining of 10 µm sections was performed using anti-LAMP1 
(1:500 Abcam) and anti-Caspase-3 Active (1:500 R&D Systems) antibodies.  
Apoptotic cell were detected with TUNEL using the Fluorescein In Situ Cell Death 
Detection Kit (Roche) according to the supplier’s protocol. Muscle sections were 
mounted with Vectashield, and photographs were taken using a fluorescence 
microscope Zeiss Axioplan 2 integrated with the AxioCam MR camera.  
Haematoxylin-eosin and PAS staining were performed according to standard 
procedures. 
Glycogen concentration was assayed in muscle lysates by measuring the amount of 
glucose released after digestion with amyloglucosidase (Aspergillus niger) using a 
commercial kit (BioVision). 
Data were expressed as µg of glycogen/mg of protein. 
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